{"title": "One-Minute Telegram Archiv - Wissen @ AMBOSS", "author": null, "url": "https://www.amboss.com/de/wissen/one-minute-telegram-archiv", "hostname": "amboss.com", "description": "This article contains a collection of content written for the One-Minute Telegram, a biweekly newsletter that presents the newest medical research condensed into just one minute of reading. This ne...", "sitename": "amboss.com", "date": "2023-10-24", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Introduction\nThis article contains a collection of content written for the One-Minute Telegram, a biweekly newsletter that presents the newest medical research condensed into just one minute of reading. This newsletter is designed for all of our colleagues who want to stay current on the latest medical literature without having to comb through and dissect medical studies themselves. It is peer-reviewed by our team of physician editors and integrated into the\n[Amboss](/de/wissen/Ohr#Z2e6489810ab8a5524d8534501fcab9be) library. Even after a long night shift or a busy day on the wards, it should go down easy. Sign up via the link in \u201cTips and Links\u201d below.\nSee also our\n[One-Minute Telegram Archiv 2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z589a0ddc97166bcc581756c355b29330), [One-Minute Telegram Archiv 2021](/de/wissen/One-Minute_Telegram_Archiv_2021#Zedc2f5a9b0e39469c09137ff9a4dcb1e) and [One-Minute Telegram Archiv 2020](/de/wissen/One-Minute_Telegram_Archiv_2020#Ze765573a3b5d8aa28f098b044fb31e6e).\nQ4 2023\n-\n[One-Minute Telegram 85-2023](/de/wissen/One-Minute_Telegram_Archiv#Z7e824584e9377de6dad3721cd5af80ba)\n-\n[One-Minute Telegram 84-2023](/de/wissen/One-Minute_Telegram_Archiv#Zfffc9e0a62f07e67ff85803a8b5f30cf)\nEdition 85 - October 21, 2023\n[ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862) no panacea for ischemic cardiogenic shock\nOne-Minute Telegram 85-2023-1/3\n10-second takeaway\nThe mortality rate in patients with cardiogenic shock after an acute myocardial infarction (MI) is high, even with prompt revascularization, but small studies have suggested that early extracorporeal life support (\n[ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862)) can improve outcomes. This large European study found that in patients with acute ischemic cardiogenic shock and planned revascularization, adding early [ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862) to usual medical therapy did not improve survival at 30 days compared to usual medical therapy alone. The search continues for ways to reduce mortality in patients with this high-risk medical condition.\nStudy breakdown\n- Study population: 420 adults aged 18\u201380 years (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age, 63 years; 81% men) with acute MI complicated by cardiogenic shock and planned early revascularization\n- Methods: multicenter, open-label trial in Germany and Slovenia\n- Randomized 1:1 to receive\n[ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862)and usual medical therapy ( [ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862)group) or usual medical therapy alone (control group)\n-\n[Percutaneous coronary intervention](/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552)was the preferred technique for revascularization.\n-\n[ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862)was started during the initial cardiac catheterization.\n- Primary outcome: death from any cause at 30 days\n- Safety outcomes: bleeding, stroke, significant peripheral vascular complications\n- Randomized 1:1 to receive\n- Main results\n- Death from any cause at 30 days was similar in the\n[ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862)group (48%) and the control group (49%): relative risk, 0.98 (95% CI, 0.80\u20131.19).\n- The rate of moderate or severe bleeding was higher in the\n[ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862)group (23%) than the control group (10%).\n- The rate of severe peripheral vascular complications was higher in the\n[ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862)group (11%) than the control group (4%).\n- Death from any cause at 30 days was similar in the\n- Limitations include:\n- The study was not blinded.\n- There was high crossover between groups, e.g., participants who had refractory cardiac arrest in the control group often received\n[ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862).\n- The heterogeneity of clinical presentations may have prevented identification of subgroups that could have benefited from\n[ECLS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862).\n- Women were underrepresented in the study.\n- Study funding: Else Kr\u00f6ner Fresenius Foundation and others\n- Original study: Extracorporeal life support in infarct-related cardiogenic shock [1]\n- Related AMBOSS articles:\n[Schock](/de/wissen/Schock#Z9b54e135690b2b7579ca9e2b356f4974)| [Akutes Koronarsyndrom](/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b)\n[Aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) and [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8): Is enteric coating beneficial?\nOne-Minute Telegram 85-2023-2/3\n10-second takeaway\n[Gastrointestinal](/de/wissen/\u00dcbersicht_des_Verdauungssystems#Zaa3f0692fb4127b17e934892e975ec10) ulceration and bleeding are potential complications of preventive treatment of [atherosclerotic cardiovascular disease](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8) ( [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)) with [aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66). This study found no difference in major bleeding events or clinical effectiveness between participants taking enteric-coated [aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) and those taking uncoated [aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66). However, further research is needed to reliably determine the effect of enteric-coated [aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) on bleeding risk, because findings suggested that enteric-coated [aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) may reduce bleeding but this could not be statistically supported.\nStudy breakdown\n- Study population: 15,076 adults aged \u2265 18 years (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age, 68 years; 68% men; 84% White, 8.4% Black, 4.5% other) with [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)not treated with an [oral]anticoagulant or [ticagrelor](/de/wissen/Thrombozytenaggregationshemmer#Zf9a34ccbcc6b56f5ba55ee8f7136ac8d)and no recent history of GI bleeding\n- Methods: post hoc secondary analysis of a pragmatic, open-label, multicenter, patient-centered randomized clinical trial (ADAPTABLE study)\n- ADAPTABLE study randomized participants 1:1 to receive\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)81 mg or 325 mg daily\n- This study further categorized participants based on their initial self-selected\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)formulation: enteric-coated or uncoated.\n- Primary effectiveness endpoint: time to first occurrence of any event in the composite of death from any cause and hospitalization for MI or stroke\n- Safety endpoint: major bleeding (i.e., hospitalization for intracranial hemorrhage or a bleeding event requiring product\n[transfusion](/de/wissen/Transfusionen#Zd803a34f176dcce85995c063e76f09f1))\n- ADAPTABLE study randomized participants 1:1 to receive\n- Main results\n- No difference in primary effectiveness of enteric-coated\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)compared to uncoated [aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66): adjusted hazard ratio (AHR), 0.94 (95% CI, 0.80\u20131.09)\n- No significant difference in the incidence of major bleeding between the enteric-coated\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)group and the uncoated [aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)group: AHR, 0.82 (95% CI, 0.49\u20131.37); large CI prevents exclusion of significance to the 18% risk reduction in bleeding\n- No difference in effectiveness or incidence of major bleeding between 81 mg and 325 mg doses in either the enteric-coated or uncoated\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)group\n- No difference in primary effectiveness of enteric-coated\n- Limitations include:\n- Patient selection of\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)formulation may have led to [confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1).\n- Any crossover between groups was not recorded.\n- Incidence of minor GI bleeding was not investigated.\n- Patient selection of\n- Study funding: Patient-Centered Outcomes Research Institute\n- Original study: Effectiveness and safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease: a secondary analysis of the ADAPTABLE randomized clinical trial [2]\n- Related AMBOSS articles:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)| [Gastrointestinale Blutung](/de/wissen/Gastrointestinale_Blutung#Zb253fc96ffb1591e2e428648851ad8c0)\nLiberal vs. tight\n[glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) control in the ICU: The sugar saga continues\nOne-Minute Telegram 85-2023-3/3\n10-second takeaway\nHyperglycemia is undisputedly associated with unfavorable outcomes in ICU patients, but the benefit of tight\n[glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) control in this group remains unclear. This large randomized control study found no difference in either length of ICU stay or 90-day mortality with tight [glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) control compared to liberal [glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) control in ICU patients who did not receive early [parenteral] nutrition. Further research is needed to clarify the optimal approach for [glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) management in ICU patients.\nStudy breakdown\n- Study population: 9230 adults (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age, 67 years; 63% men) admitted to ICUs in Belgium\n- Methods: prospective, multicenter, randomized, controlled, parallel group trial\n- Randomized 1:1 to target\n[glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57)of 180\u2013215 mg/dL (liberal [glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57)control) or 80\u2013110 mg/dL (tight [glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57)control)\n-\n[Insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)administration was guided by a computer algorithm and given as a continuous [infusion](/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81)through a central venous catheter.\n-\n[Enteral]nutrition was started as soon as possible, but no [parenteral]nutrition was given in the first week.\n- Primary outcome: length of required ICU care\n- Secondary outcomes included severe\n[acute kidney injury](/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4)( [AKI](/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4)) and liver dysfunction.\n- Safety outcome: mortality at 90 days\n- Randomized 1:1 to target\n- Main results\n- Length of required ICU care was similar in the tight-control group and the liberal-control group: HR, 1 (95% CI, 0.96\u20131.04).\n- Mortality at 90 days was similar in the tight-control group (10.5%) and the liberal-control group (10.1%).\n- Severe hypoglycemia occurred more frequently in the tight-control group (1%) than in the liberal-control group (0.7%).\n- Incidences of severe\n[AKI](/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4)and liver dysfunction were lower in the tight-control group.\n- Limitations include:\n- The study was not blinded.\n- Change in discharge policies during the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)pandemic may have led to [confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1).\n- Study funding: Research Foundation-Flanders and others\n- Original study: Tight blood-\n[glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57)control without early parenteral nutrition in the ICU [3]\n- Related AMBOSS articles:\n[Insulinkorrektur bei Hyperglyk\u00e4mie](/de/wissen/Diabetes_mellitus#Z9b391484e159ca36f77f4655461c0450)\nEdition 84 - October 7, 2023\nContinue monitoring BP during pregnancy\nOne-Minute Telegram 84-2023-1/3\n10-second takeaway\nHypertensive disorders of pregnancy (HDP) are a leading cause of maternal morbidity and mortality and can result in adverse outcomes for the\n[fetus](/de/wissen/Physiologische_Aspekte_pr\u00e4-_und_postnatal#Zfa6180c135c11222f20e4c1c738186b1) and newborn. The USPSTF has reaffirmed its previous recommendation to screen for HDP with blood pressure (BP) measurements at all prenatal care visits. Individuals with positive screening should receive evidence-based management.\nRecommendation breakdown\n- Recommendation: The USPSTF concluded with moderate certainty that obtaining BP measurements throughout pregnancy to screen for HDP has substantial benefit.\n- Applicable population: all pregnant individuals with no history of HDP or preexisting hypertension\n- Additional information\n- Recommendations for HDP screening\n- Obtain BP measurements at every prenatal care visit.\n- Ensure that the appropriate cuff size is used.\n- If systolic BP is \u2265 140 mm Hg or diastolic \u2265 90 mm Hg, repeat the measurement after at least 4 hours to confirm the finding.\n- Test for proteinuria if screening is positive.\n- During the postpartum period:\n- Educate on clinical features of preeclampsia.\n- Continue BP measurements for individuals with HDP.\n- There is limited evidence that screening for HDP is associated with severe or significant harm.\n- Potential harms of treatment include:\n- Preterm or cesarean delivery\n- Neonatal complications\n- Adverse drug effects\n- Recommendations for HDP screening\n- Limitations include:\n- Insufficient research on:\n- Screening for HDP during the postpartum period\n- Effect of screening on maternal and\n[perinatal]morbidity and mortality\n- Insufficient research on:\n- Study funding: Agency for Healthcare Research and Quality (AHRQ)\n- Original study: Screening for hypertensive disorders of pregnancy: US Preventive Services Task Force final recommendation statement [4]\n- Related AMBOSS articles:\n[Hypertensive Schwangerschaftserkrankungen](/de/wissen/Hypertensive_Schwangerschaftserkrankungen#Zba4240f962fd7e4712a40becf9b43e84)| [Vorsorgeuntersuchungen in der Schwangerschaft](/de/wissen/Vorsorgeuntersuchungen_in_der_Schwangerschaft#Z2b7f8151a4f6a203e695b45aabb57fd8)\nBuprenorphine in the\n[fentanyl](/de/wissen/Opioide#Z9d43413a5f7e7cb1d1b517ae170633bc) era\nOne-Minute Telegram 84-2023-2/3\n10-second takeaway\nWhile buprenorphine is an effective treatment for\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) use disorder (OUD), the current recommended maintenance dose of 16 mg/day may not be adequate for individuals who use [fentanyl](/de/wissen/Opioide#Z9d43413a5f7e7cb1d1b517ae170633bc), which is now the leading cause of [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)-related overdose death in the US. In this study, higher doses of buprenorphine were associated with greater OUD treatment retention in a setting where recreational use of [fentanyl](/de/wissen/Opioide#Z9d43413a5f7e7cb1d1b517ae170633bc) is widespread. Further research is necessary to determine if higher doses of buprenorphine should be given to individuals who use [fentanyl](/de/wissen/Opioide#Z9d43413a5f7e7cb1d1b517ae170633bc) to better mitigate [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) withdrawal symptoms and [cravings].\nStudy breakdown\n- Study population: 6499 adults (61% male; 57% aged 25\u201344 years) starting a sublingual buprenorphine formulation for OUD treatment for the first time\n- Methods: retrospective cohort study\n- Data was extracted from the Rhode Island Prescription Drug Monitoring Program.\n- Exposure: daily buprenorphine dose; primary analysis compared buprenorphine 16 mg and 24 mg; exploratory analyses included 8 mg\n- Participants were monitored using prescription fill dates and days\u2019 supply.\n- Primary outcome: time to buprenorphine discontinuation\n- Follow-up: 180 days\n- Main results\n- Treatment discontinuation was higher in participants prescribed buprenorphine 16 mg than in those prescribed buprenorphine 24 mg daily.\n- 59% vs. 53% (P = 0.005)\n- Adjusted HR, 1.20 (95% CI, 1.06\u20131.37)\n- Time to treatment discontinuation was similar in participants prescribed buprenorphine 8 mg and 16 mg daily.\n- Treatment discontinuation was higher in participants prescribed buprenorphine 16 mg than in those prescribed buprenorphine 24 mg daily.\n- Limitations include:\n- Results may have been influenced by unmeasured confounders given the retrospective study design.\n- Not generalizable to individuals taking daily buprenorphine doses higher than 24 mg or other buprenorphine formulations, or those treated in health care settings other than outpatient settings\n- Further research is needed on the risks and benefits of buprenorphine doses higher than 24 mg.\n- Study funding: National Institute on Drug Abuse\n- Original study: Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl [5]\n- Related AMBOSS articles:\n[Opioide (Intoxikation und Abh\u00e4ngigkeit)](/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z2617c4a1c8650f5bf241213ea0311b58)| Substitutionsbehandlung bei Opioidabh\u00e4ngikeit | Akute [Opioidintoxikation](/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z76aa6b4f42cf89c1f5aca166ccf1f874)\nA STEP in the right direction for obesity-related\n[HFpEF](/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3)\nOne-Minute Telegram 84-2023-3/3\n10-second takeaway\nIndividuals with heart failure with preserved ejection fraction (\n[HFpEF](/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3)) and obesity experience more severe functional impairment and heart failure ( [HF](/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4)) symptoms than those with [HFpEF](/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3) without obesity. In this study, the use of semaglutide resulted in reduced [HF](/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4)-related symptoms, enhanced physical functionality, and significant weight loss compared to [placebo]. These findings suggest that treatments such as semaglutide may meaningfully improve outcomes for patients with obesity and [HFpEF](/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3).\nStudy breakdown\n- Study population: 529 adults (mean age 69 years; 56% female; 96% White) with\n[LVEF]\u2265 45%, [NYHA](/de/wissen/Herzinsuffizienz#Zf4df35c22cb16c63ac506d4eed4b8277)class II\u2013IV, and [BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04)\u2265 30 kg/m2\n- Methods: international, randomized, double-blind,\n[placebo]-controlled trial (STEP- [HFpEF](/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3)trial)\n- Randomized 1:1 to receive once-weekly semaglutide (starting dose 0.25 mg for 4 weeks, titrated to 2.4 mg by week 16) or\n[placebo]for 52 weeks\n- Stratified by\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04): < 35 or \u2265 35 kg/m2\n- No participants underwent bariatric surgery, but some received other weight-loss treatments.\n- Primary endpoints\n- Change in\n[HF](/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4)-related symptoms, physical function, QoL, and social function (based on a cardiomyopathy questionnaire)\n- Change in body weight\n- Change in\n- Follow-up: 5 weeks after end of treatment (i.e., week 57)\n- Randomized 1:1 to receive once-weekly semaglutide (starting dose 0.25 mg for 4 weeks, titrated to 2.4 mg by week 16) or\n- Main results\n- Compared to the\n[placebo]group, participants in the semaglutide group had:\n- A greater improvement in\n[HF](/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4)-related symptoms, physical function, QoL, and social function\n- Greater weight loss: -13.3% vs. -2.6%\n[total body weight](estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4)\n- Lower rate of serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)(including cardiac events): 13.3% vs. 26.7%\n- A greater improvement in\n- The rate of treatment discontinuation due to serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)was similar in both groups.\n- Compared to the\n- Limitations include:\n- Limited generalizability given the exclusion of individuals with:\n- > 5 kg change in body weight 90 days prior to screening\n- History of diabetes\n- White individuals were overrepresented in the study.\n- Limited generalizability given the exclusion of individuals with:\n- Study funding: Novo Nordisk\n- Original study: Semaglutide in patients with heart failure with preserved ejection fraction and obesity [6]\n- Related AMBOSS articles:\n[HFpEF](/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3)\nQ3 2023\n-\n[One-Minute Telegram 83-2023](/de/wissen/One-Minute_Telegram_Archiv#Z8eb8ab88ce8c9bcad538e75ef0f4f477)\n- Hormonal contraception and\n[NSAIDs](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e): a risky tango\n- The OPTIMAL-BP after endovascular thrombectomy for stroke\n- Older adults benefit from complete revascularization after acute MI\n- Hormonal contraception and\n-\n[One-Minute Telegram 82-2023](/de/wissen/One-Minute_Telegram_Archiv#Z09756718c7d204b204e1cd78fe5e0c7a)\n-\n[One-Minute Telegram 81-2023](/de/wissen/One-Minute_Telegram_Archiv#Zb80a07416434b8291c7968e6acfd153a)\n- Swift lift for postpartum\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)\n- Hypertension and the ill-fitting blood pressure cuff\n- Clearing the way: targeting\n[amyloid](/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9)plaques in [Alzheimer](/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874)disease\n- Swift lift for postpartum\n-\n[One-Minute Telegram 80-2023](/de/wissen/One-Minute_Telegram_Archiv#Z463c8c90088c3f50831a5fc26e2465bc)\n-\n[One-Minute Telegram 79-2023](/de/wissen/One-Minute_Telegram_Archiv#Ze776aa3e9343ef527988f9c7d3c5ba5f)\n- Spill the T:\n[testosterone](/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3)safety in men with CVD\n- Does\n[vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)supplementation reduce cardiovascular risk?\n- Revisiting an old drug for smoking cessation\n- Spill the T:\n-\n[One-Minute Telegram 78-2023](/de/wissen/One-Minute_Telegram_Archiv#Z52894ed8a09e8067dffaa93a5a611761)\n- USPSTF recommends screening adults for major\n[depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)disorder and anxiety disorders\n- Promising potential for a once-weekly basal\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)analog\n- Is bempedoic\n[acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f)an effective alternative for patients with [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)intolerance?\n- USPSTF recommends screening adults for major\n-\n[One-Minute Telegram 77-2023](/de/wissen/One-Minute_Telegram_Archiv#Z890df07b26e65528d01c5125af1e188c)\nEdition 83 - September 23, 2023\nHormonal contraception and\n[NSAIDs](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e): a risky tango\nOne-Minute Telegram 83-2023-1/3\n10-second takeaway\nHormonal contraceptives and nonsteroidal antiinflammatory drugs (\n[NSAIDs](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e)) independently increase the risk of venous thromboembolism (VTE), but the risk with concomitant use is not well studied. In this national cohort study, the adjusted incidence rate ratio (AIRR) of VTE in women aged 15\u201349 years was higher in those who used [NSAIDs](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e) than in those who did not; the incidence was highest in women with concomitant use of [NSAIDs](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e) and medium- or high-risk hormonal contraception. Women using both [NSAIDs](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e) and hormonal contraception should be advised about the increased risk of VTE.\nStudy breakdown\n- Study population: all women aged 15\u201349 years living in Denmark between 1996 and 2017 without a history of venous or arterial thrombotic events, cancer, thrombophilia, hysterectomy, oophorectomy, sterilization, or infertility treatment (\u223c 2 million)\n- Methods: nationwide historical cohort study\n- Information was obtained from national registries.\n- Timing and duration of nonaspirin\n[NSAID](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e)and hormonal contraceptive use was derived from filled prescription data.\n- Based on current understanding, hormonal contraceptives were classified according to VTE risk: high, medium, or low/no risk.\n- Primary outcome: first diagnosis of lower extremity deep venous thrombosis or pulmonary embolism\n- Follow-up:\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)of 10 years\n- Main results\n- The AIRR of VTE was highest with concomitant use of\n[NSAIDs](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e)and higher-risk hormonal contraception.\n- No use of\n[NSAIDs](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e)or hormonal contraception: AIRR = 1.0 (reference)\n-\n[NSAID](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e)use only: 7.2 (95% CI, 6.0\u20138.5)\n- Hormonal contraceptive use only\n- Low or no risk: 1.1 (1.0\u20131.2)\n- Medium risk: 3.0 (2.8\u20133.2)\n- High risk: 4.1 (3.9\u20134.3)\n- Concomitant use\n- The AIRR of VTE was highest with concomitant use of\n- Limitations include:\n- Determination of\n[NSAID](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e)and contraceptive use was based on filled prescriptions rather than direct observation.\n- Some potential confounders (e.g., smoking, obesity) were not adjusted for.\n- Results may not be generalizable to patients from groups that are underrepresented in the Danish population.\n- Determination of\n- Study funding: Danish Heart Foundation\n- Original study: Venous thromboembolism with use of hormonal contraception and\n[non-steroidal anti-inflammatory drugs](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e): nationwide cohort study [7]\n- Related AMBOSS articles:\n[Phlebothrombose](/de/wissen/Phlebothrombose#Z28ca7507422e8791c7b034c316a126e1)| [Lungenembolie](/de/wissen/Lungenembolie#Z109ebdc29405d0f0b7670dc604254fcd)\nThe OPTIMAL-BP after endovascular thrombectomy for stroke\nOne-Minute Telegram 83-2023-2/3\n10-second takeaway\nCurrent guidelines recommend maintaining systolic blood pressure (\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)) under 180 mm Hg after successful endovascular thrombectomy (EVT) for acute ischemic stroke (AIS), but optimal [SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58) targets for decreasing the risk of intracerebral hemorrhage (ICH) and cerebral edema remain unknown. This trial found that intensive blood pressure control during the initial 24 hours after successful EVT for AIS led to worse functional outcomes at 3 months compared to conventional management. Conventional management remains the preferred strategy following EVT for AIS.\nStudy breakdown\n- Study population: 306 South Korean adults aged \u2265 20 years (mean age 73 years; 40% women) with an AIS caused by large vessel occlusion who underwent successful reperfusion with EVT and had\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)\u2265 140 mm Hg within 2 hours after the procedure\n- Methods: multicenter, prospective, randomized, open-label, blinded end-point clinical trial (OPTIMAL-BP trial)\n- Randomized 1:1 to intensive management (\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)target < 140 mm Hg) or conventional management ( [SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)target 140\u2013180 mm Hg) for 24 hours after reperfusion\n- Noninvasive\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)was continuously monitored.\n- Nicardipine was the preferred antihypertensive (other medications could be used at the physician\u2019s discretion).\n- In the conventional management group,\n[vasopressors]were not used to maintain [SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)\u2265 140 mm Hg but IV fluids and/or [inotropes](/de/wissen/Herzmechanik#Z3ec8a19368d15af640816443577a9cf5)could be used to treat clinically significant hypotension.\n- Neuroimaging was performed after 24 hours or if neurological symptoms worsened.\n- Primary outcome: functional independence at 3 months\n- Primary safety outcomes\n- Symptomatic ICH within 36 hours\n- Death related to the index stroke within 3 months\n- Secondary outcomes included occurrence of malignant brain edema within 36 hours.\n- Randomized 1:1 to intensive management (\n- Main results\n- The trial was terminated early because of safety concerns in the intensive management group.\n- Functional independence at 3 months was significantly lower with intensive management than with conventional management: 39% vs. 54% (risk difference, -15.1%; 95% CI, -26.2% to -3.9%).\n- Malignant brain edema occurred more frequently with intensive management than conventional management: adjusted OR, 7.88 (1.57 to 39.39).\n- Rates of death and symptomatic ICH were similar in both groups.\n- Limitations include:\n- Potential\n[selection bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de)given that < 20% of screened patients were randomized\n- The trial was terminated early, which may have limited the statistical\n[power](/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e).\n- Limited generalizability\n- Conducted in South Korea only\n- Multiple exclusion criteria, e.g., prestroke disability, serious comorbidities\n- Potential\n- Study funding: Ministry of Health and Welfare, Republic of Korea\n- Original study: Intensive vs conventional blood pressure lowering after endovascular thrombectomy in acute ischemic stroke: the OPTIMAL-BP randomized clinical trial [8]\n- Related AMBOSS article:\n[Isch\u00e4mischer Schlaganfall](/de/wissen/Isch\u00e4mischer_Schlaganfall#Z132d7774d1cef997981d05c36a439551)\nOlder adults benefit from complete revascularization after acute MI\nOne-Minute Telegram 83-2023-3/3\n10-second takeaway\nComplete revascularization using\n[percutaneous coronary intervention](/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552) ( [PCI](/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552)) to treat nonculprit lesions is known to be beneficial in younger patients after an acute myocardial infarction (MI), but this approach is not well studied in older patients. In this trial, older patients who underwent physiology-guided complete revascularization had better outcomes than those who underwent culprit-only revascularization. Complete revascularization with [PCI](/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552) after an acute MI should not be withheld based on age alone.\nStudy breakdown\n- Study population: 1445 adults aged \u2265 75 years (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age 80 years, 37% women) with an acute MI (35% [STEMI](/de/wissen/Myokardinfarkt#Za340e577f9ff67b72ee87080e1d8758b)) who had successful [PCI](/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552)of the culprit lesion and had additional significant-appearing coronary artery disease\n- Methods: international (Italy, Spain, Poland), multicenter, randomized trial (FIRE trial)\n- Randomized 1:1 to physiology-guided complete revascularization or culprit lesion-only revascularization\n- Guideline-based medical therapy was used in both groups.\n- Primary outcome: composite of death, MI, stroke, or coronary revascularization for ischemia at 1 year\n- Secondary outcome: composite of cardiovascular death or MI\n- Safety outcome: composite of contrast-associated\n[acute kidney injury](/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4), stroke, or bleeding\n- Follow-up: 1 year\n- Main results\n- Fewer outcome events were reported in the complete revascularization group than in the culprit-only group.\n- The occurrence of individual components of the primary outcome (excluding stroke) was significantly lower in the complete revascularization group than in the culprit-only group.\n- Safety outcomes were similar in both groups.\n- Limitations include:\n- Nonblinded design\n- Generalizability to treatments that do not utilize\n[sirolimus](/de/wissen/Immunsuppressiva#Z243798dbd864f1f85dfbc0f0feeaa79c)-eluting [stents]is limited.\n- Patients with the following were excluded:\n- Culprit coronary artery not clearly identified\n- Nonculprit lesion in the left main coronary artery\n- Planned or previous surgical revascularization\n- Life expectancy < 1 year\n- Study funding: Sahajanand Medical Technologies, Medis Medical Imaging Systems, Eukon, Siemens Healthineers, General Electric Healthcare, and Insight Lifetech\n- Original study: Complete or culprit-only\n[PCI](/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552)in older patients with myocardial infarction [9]\n- Related AMBOSS article:\n[Akutes Koronarsyndrom](/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b)\nEdition 82 - September 9, 2023\nProtect with\n[PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)\nOne-Minute Telegram 82-2023-1/3\n10-second takeaway\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604) affects over one million individuals in the US. The United States Preventive Services Task Force (USPSTF) has reaffirmed its previous recommendation to offer preexposure prophylaxis ( [PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)) to individuals at increased risk of [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604) acquisition and added evidence for the [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f) of newer [PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2) formulations. The use of [PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2) should be based on shared decision-making between the patient and the prescribing clinician.\nRecommendation breakdown\n- Recommendation: The USPSTF concluded with high certainty that there is a substantial benefit to using\n[PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)to decrease the risk of acquiring [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)in individuals at increased risk.\n- Applicable population\n- Sexually active\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)-negative adolescents and adults with any of the following:\n-\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)-negative persons who inject drugs and share drug-injection equipment with a partner who is [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)-positive or who shares injection equipment with others\n- Sexually active\n- Additional information\n- Acute and chronic\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)must be ruled out prior to initiating [PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2).\n- Other recommended pre-\n[PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)assessments include:\n- Pregnancy testing\n-\n[STI](/de/wissen/Sexuell_\u00fcbertragbare_Infektionen#Zf2a474fc86c5ef68694e80ca13cd405b)screening\n- Kidney function testing\n-\n[Hepatitis B](/de/wissen/Hepatitis_B_und_HBV-Infektion#Z0cc1ba9a62130e5544df273f6b9fb8aa)serology\n-\n[Lipid](/de/wissen/Lipide#Z8c94ec3e8e06e82aa0ca6a93b74d282d)profile testing\n-\n[Tenofovir](/de/wissen/Virostatika#Zf735d1aa1d436e2f0fe90a8a8c71d4af)-based [oral]formulations and injectable [cabotegravir](/de/wissen/HIV-Infektion#Z2df1d847fdbe4b665b60d68dc7e4f76f)are [FDA]-approved for [PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)in individuals weighing \u2265 35 kg (77 lbs).\n- Continued condom use is recommended, as the time from initiation of\n[PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)to full protection from [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)is unknown and [PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)does not provide protection from other [STIs](/de/wissen/Sexuell_\u00fcbertragbare_Infektionen#Zf2a474fc86c5ef68694e80ca13cd405b).\n- Acute and chronic\n- Potential harms of\n[PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)use include:\n- Initiation of\n[PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)in individuals with preexisting [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)may lead to the development of drug [resistance](/de/wissen/Lungenfunktionsuntersuchung#Z80d949a4d2a4efc1d0698d7d68ac9d2b).\n- Kidney injury (with\n[tenofovir](/de/wissen/Virostatika#Zf735d1aa1d436e2f0fe90a8a8c71d4af)-based formulations)\n- Weight gain (with\n[cabotegravir](/de/wissen/HIV-Infektion#Z2df1d847fdbe4b665b60d68dc7e4f76f))\n- Initiation of\n- Limitations include:\n- The USPSTF does not offer recommendations regarding\n[PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)in persons weighing < 35 kg (77 lbs).\n- While the\n[FDA]has approved the use of [tenofovir](/de/wissen/Virostatika#Zf735d1aa1d436e2f0fe90a8a8c71d4af)disoproxil fumarate/emtricitabine for [PrEP](/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2)in pregnant individuals, data regarding its safety and [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)during pregnancy and breastfeeding is limited.\n- Further research is needed on:\n- The USPSTF does not offer recommendations regarding\n- Study funding: Agency for Healthcare Research and Quality (AHRQ)\n- Original study: Preexposure prophylaxis to prevent acquisition of\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)[10]\n- Related AMBOSS article:\n[HIV-Infektion](/de/wissen/HIV-Infektion#Z54541a53e014f60bb262be162cea06e7)\nDon\u2019t trust, always verify: AI generates fake medical citations\nOne-Minute Telegram 82-2023-2/3\n10-second takeaway\nThe use of artificial intelligence (AI) in medical education and research has the potential to improve efficiency, but the content it produces is not always reliable. This study found that ChatGPT cited fake journal articles and did not include the most recent developments. Although a chatbot may be a helpful tool, it has limitations and can generate unreliable information.\nStudy breakdown\n- Study purpose: to quantify OpenAI\u2019s ChatGPT-3.5 and ChatGPT-4 citation error rate\n- Methods\n-\n[GPT](/de/wissen/Laboratoriumsmedizin#Zee26dc10887db5c92bedaa1d1cc3e6c1)-3.5 and [GPT](/de/wissen/Laboratoriumsmedizin#Zee26dc10887db5c92bedaa1d1cc3e6c1)-4 were used to generate discussion on topics relating to learning health systems (LHS) on both a general (e.g., LHS and data) and specific (e.g., creating a stroke risk prediction model) level. The chatbot was engaged with systematically ordered prompts comprising the following elements:\n- Topic context (e.g., \u201cLHS vision will transform our health care systems.\u201d)\n- Topic question (e.g., \u201cWhat is LHS?\u201d)\n- Request for references (e.g., \u201cProvide some journal articles for LHS as a reference.\u201d)\n- Each journal article cited by the chatbot was verified; if a citation could not be verified, it was considered fake.\n-\n- Main results\n- 159/162 (98.1%) of citations provided by the\n[GPT](/de/wissen/Laboratoriumsmedizin#Zee26dc10887db5c92bedaa1d1cc3e6c1)-3.5 model were found to be fake (95% CI, 94.7\u201399.6%).\n- 53/257 (20.6%) of citations provided by the\n[GPT](/de/wissen/Laboratoriumsmedizin#Zee26dc10887db5c92bedaa1d1cc3e6c1)-4 model were found to be fake (95% CI, 15.8\u201326.1%).\n- Fake citations were more likely to be generated with specific discussions than general ones.\n- The chatbot did not provide information on the latest advances in LHS.\n- 159/162 (98.1%) of citations provided by the\n- Limitations include: Since the study only tested topics related to LHS, the findings may not be generalizable to other areas of medical research.\n- Study funding: Unknown\n- Original study: Accuracy of chatbots in citing journal articles [11]\n- Related AMBOSS article:\n[Studientypen der medizinischen Forschung](/de/wissen/Studientypen_der_medizinischen_Forschung#Z91064578493b1b11a03044f853e7eec6)\n[COX](/de/wissen/Gewebshormone#Zd51752a55c3c4527e4b42765f0bc965a) blocking to prevent unwanted pregnancy\nOne-Minute Telegram 82-2023-3/3\n10-second takeaway\n[Levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87) emergency contraception (EC) is used to prevent unwanted pregnancy, but is not effective if used after [ovulation](/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa) has occurred. In this trial, coadministration of [levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87) with piroxicam, a long-acting [cyclooxygenase](/de/wissen/Gewebshormone#Zd51752a55c3c4527e4b42765f0bc965a) ( [COX](/de/wissen/Gewebshormone#Zd51752a55c3c4527e4b42765f0bc965a)) inhibitor, within 72 hours of unprotected sex prevented a higher proportion of pregnancies than expected based on an established model compared to [levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87) and [placebo]. Use of a [COX](/de/wissen/Gewebshormone#Zd51752a55c3c4527e4b42765f0bc965a) inhibitor in combination with [levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87) may increase the [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f) of EC.\nStudy breakdown\n- Study population: 860 women aged \u2265 18 years (mean age 30 years) in Hong Kong who requested EC within 72 hours of unprotected sex\n- Methods: randomized, double-blind,\n[placebo]-controlled trial\n- Randomized 1:1 to\n[levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87)1.5 mg plus piroxicam 40 mg PO once or [levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87)1.5 mg plus [placebo]PO once\n- Primary outcome: proportion of pregnancies prevented compared to pregnancies expected\n- Secondary outcomes: pregnancy rate after EC, change in menstrual pattern, nonmenstrual bleeding, and other\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)\n- Follow-up: 1\u20132 weeks after expected menstrual period\n- Randomized 1:1 to\n- Main results\n- A greater proportion of expected pregnancies were prevented in the piroxicam group (94.7%) than in the\n[placebo]group (63.4%).\n- Pregnancy rate was 0.2% in the piroxicam group compared to 1.7% in the\n[placebo]group (OR, 0.20; 95% CI, 0.02\u20130.91).\n- Changes in menstrual pattern, nonmenstrual bleeding, and adverse effects were similar between groups.\n- The most common\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)within the first 3 days included [fatigue]or weakness, nausea, and lower abdominal pain.\n- A greater proportion of expected pregnancies were prevented in the piroxicam group (94.7%) than in the\n- Limitations include:\n- Limited generalizability given multiple exclusion criteria, including:\n- Current or recent use of hormonal contraception or\n[NSAIDs](/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e)\n- > 1 episode of unprotected sex in the current menstrual cycle\n-\n[Absence](/de/wissen/Epileptische_Anf\u00e4lle_und_Epilepsien#Z93dedd171a6efaddb5d27c931860ee21)of menses after a recent abortion or during the postpartum period\n- Unknown last menstrual period date\n- Current use of certain medications (e.g., anticoagulants)\n- History of certain medical conditions (e.g., hypertension,\n[urticaria](/de/wissen/Urtikaria#Ze61f2088492f0f613c664c8409095649))\n- Current or recent use of hormonal contraception or\n- Some groups were underrepresented in the study, including women with overweight, obesity, and/or a non-Chinese ethnicity, further limiting generalizability.\n- Limited generalizability given multiple exclusion criteria, including:\n- Study funding: None\n- Original study:\n[Oral]emergency contraception with [levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87)plus piroxicam: a randomised double-blind [placebo]-controlled trial [12]\n- Related AMBOSS article:\n[Orale Kontrazeptiva](/de/wissen/Hormonelle_Kontrazeption#Zc3fe73a267b5941350cfd7fee8e1f20a)\nEdition 81 - August 26, 2023\nSwift lift for postpartum\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)\nOne-Minute Telegram 81-2023-1/3\n10-second takeaway\nPostpartum\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473) (PPD) affects almost one in five new mothers, but it can take weeks to months for standard-of-care antidepressants to take effect. In this trial, [oral] zuranolone, a neuroactive [steroid] GABAA receptor modulator, was more effective than [placebo] in improving symptoms of PPD, with a [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b) time to improvement of only 9 days. This is the first [FDA]-approved rapid-acting [oral] medication for the treatment of PPD.\nStudy breakdown\n- Study population\n- 196 adults aged 18\u201345 years with severe PPD\n- 70% White, 22% Black, 8% other; 38% Hispanic\n- Methods: phase 3 randomized, double-blind,\n[placebo]-controlled trial\n- Randomized 1:1 to zuranolone 50 mg PO or\n[placebo]daily for 14 days\n- The severity of\n[depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)symptoms was measured at [baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293)and at days 3, 15, 28, and 45.\n- Primary\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)endpoint: change in [depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)severity from [baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293)to day 15\n- Key secondary endpoints\n- Change in\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)severity at days 3, 28, and 45\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)time to improvement\n- Change in\n- Safety and tolerability: Adverse effects and dropout rates were recorded.\n- Follow-up: 45 days\n- Randomized 1:1 to zuranolone 50 mg PO or\n- Main results\n- Participants in the zuranolone group had significant improvement of\n[depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)symptoms compared to those in the [placebo]group at all measured time points.\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)time to symptom improvement: 9 days in the zuranolone group compared to 43 days in the [placebo]group\n- The most common adverse effects, reported in > 10% of participants, were somnolence,\n[dizziness](/de/wissen/Schwindel#Ze8b4c0f0c55909252ceee5f1b6b3fbc5), and [sedation](/de/wissen/Analgosedierung#Z5c1013b0f02ccf1b6601a686f30f20a7).\n- One patient in the zuranolone group ended participation because of adverse effects.\n- Participants in the zuranolone group had significant improvement of\n- Limitations include:\n- Individuals with a history of other psychiatric conditions were excluded.\n- Only individuals with severe PPD were included in the study.\n- Study funding: Sage Therapeutics and Biogen\n- Original study: Zuranolone for the treatment of postpartum\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)[13]\n- Related AMBOSS article:\n[Postpartale Depression](/de/wissen/Wochenbett#Z8860d9e8ee48d98710828dcee3035d78)| [Unipolare Depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)\nHypertension and the ill-fitting blood pressure cuff\nOne-Minute Telegram 81-2023-2/3\n10-second takeaway\nAccurate blood pressure (BP) measurement is required for optimal management of cardiovascular disease, but health care providers frequently use an inappropriately sized BP cuff when obtaining these measurements. In this study, using an automated BP device with a regular-size BP cuff rather than a specifically sized BP cuff resulted in inaccurate systolic blood pressure (\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)) measurements. Training medical staff on correct BP measurement procedures can improve patient care.\nStudy breakdown\n- Study population: 195 community-dwelling adults aged \u2265 18 years (mean age 54 years)\n- 66% female; 68% Black, 30% White; 3% Hispanic\n- 51% with hypertension; mean\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04)28.8 kg/m2\n- Methods: randomized crossover trial\n- The appropriate cuff size was determined using mid-upper arm circumference.\n- Participants had four sets of BP measurements with an automated device: two with an appropriately sized cuff, one with an undersized cuff, and one with an oversized cuff (each set included a measurement with a regular-size cuff, which could be appropriately or inappropriately sized, depending on the patient).\n- Primary outcome: difference in\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)obtained with a regular-size BP cuff compared to a specifically sized BP cuff\n- Secondary outcome: difference in\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)obtained with an oversized or undersized cuff compared to an appropriately sized BP cuff\n- Main results\n- The use of a regular-size BP cuff resulted in inaccurate\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)measurements if it did not fit appropriately.\n- Individuals who needed a small BP cuff:\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)was lower with a regular-size cuff than with a small cuff (mean [SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)difference, -3.6 mm Hg; 95% CI, -5.6 to -1.7).\n- Individuals who needed a large or extra-large BP cuff:\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)was higher with a regular-size cuff than with a large (mean [SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)difference, 4.8 mm Hg; 95% CI, 3.0 to 6.6) or extra-large BP cuff (mean [SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)difference, 19.5 mm Hg; 95% CI, 16.1 to 22.9).\n- Individuals who needed a small BP cuff:\n- The difference between\n[SBP](/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58)obtained with an appropriately sized cuff and that obtained with an inappropriately sized one was greatest in those who required a large or extra-large BP cuff.\n- The use of a regular-size BP cuff resulted in inaccurate\n- Limitations include:\n- The incidence of hypertension and obesity varied between the different groups, which may have led to\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1).\n- Findings are not generalizable to pregnant individuals, those with an arm circumference > 55 cm, or those with arteriovenous shunts in both arms.\n- The incidence of hypertension and obesity varied between the different groups, which may have led to\n- Study funding: Resolve to Save Lives\n- Original study: Effects of cuff size on the accuracy of blood pressure readings: the cuff(SZ) randomized crossover trial [14]\n- Related AMBOSS article:\n[Arterielle Hypertonie](/de/wissen/Arterielle_Hypertonie#Z3d73ccc1b405184a8d3087bd8b727eb4)\nClearing the way: targeting\n[amyloid](/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9) plaques in [Alzheimer](/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874) disease\nOne-Minute Telegram 81-2023-3/3\n10-second takeaway\nDeposition of \u03b2-\n[amyloid](/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9) in the brain is an early finding in [Alzheimer](/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874) disease, and recent research has suggested that targeting the [amyloid](/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9) cascade with monoclonal antibodies may slow disease progression. In this phase 3 trial, donanemab significantly slowed [Alzheimer](/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874) disease progression and decreased brain [amyloid](/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9) plaque levels compared to [placebo]. Monoclonal antibody therapy may be a promising new treatment for symptomatic patients with early [Alzheimer](/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874) disease.\nStudy breakdown\n- Study population: 1736 adults aged 60\u201385 years (mean age 73 years) with early symptomatic\n[Alzheimer](/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874)disease and abnormal [amyloid](/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9)and tau pathology on [PET](/de/wissen/Nuklearmedizin_und_Strahlenschutz#Z1629e94315efb089ad493dbb7ff5a6f1)imaging\n- 57% women; 92% White\n- 68% with low/medium tau pathology, 32% with high tau pathology\n- Methods: phase 3 multicenter, randomized, double-blind, parallel,\n[placebo]-controlled trial\n- Randomized 1:1 to IV donanemab (700 mg for the first 3 doses, then 1400 mg) or\n[placebo]every 4 weeks for 72 weeks\n- Groups were stratified by tau pathology level: low/medium or combined (low/medium and high).\n- Cognition and daily function were assessed using the integrated\n[Alzheimer](/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874)Disease Rating Scale (iADRS).\n- Imaging for\n[amyloid](/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9)monitoring was performed at 4, 12, 24, 52, and 76 weeks.\n- Primary outcome: change in iADRS score from\n[baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293)to week 76\n- Secondary outcomes included:\n-\n[Amyloid](/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9)plaque reduction at week 76 [Adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)\n-\n- Randomized 1:1 to IV donanemab (700 mg for the first 3 doses, then 1400 mg) or\n- Main results\n- Disease progression was slower with donanemab than with\n[placebo]in both tau pathology populations.\n- 35% slower disease progression in the low/medium tau population (95% CI, 19.90\u201350.23%)\n- 22% slower disease progression in the combined tau population (95% CI, 11.38\u201333.15%)\n- There was a greater decrease in brain\n[amyloid](/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9)plaque levels in the donanemab group than in the [placebo]group.\n- The incidence of serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)was higher in the donanemab group than in the [placebo]group.\n- Brain edema or effusion on planned imaging (24.0% vs. 2.1%)\n-\n[Infusion](/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81)-related reactions (8.7% vs. 0.5%)\n- Death (1.9% vs. 1.1%)\n- Disease progression was slower with donanemab than with\n- Limitations include:\n- Participants were predominantly White, limiting generalizability to other racial and ethnic groups.\n- Follow-up was limited to 76 weeks.\n- Study funding: Eli Lilly and Company\n- Original study: Donanemab in early symptomatic\n[Alzheimer](/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874)disease: the TRAILBLAZER-ALZ 2 randomized clinical trial [15]\n- Related AMBOSS articles:\n[Morbus Alzheimer](/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874)\nEdition 80 - August 12, 2023\nPitavastatin to prevent CVD in\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)\nOne-Minute Telegram 80-2023-1/3\n10-second takeaway\nIndividuals with\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604) have an increased risk of cardiovascular disease (CVD), highlighting the importance of preventive lifestyle and pharmacological interventions to promote cardiac health. This study showed that, compared to [placebo], pitavastatin, a [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25) that has minimal drug-drug interactions with antiretroviral therapy ( [ART](/de/wissen/HIV-Infektion#Z8085d2401472cb7e809cfc2fe50faf6c)), can reduce the risk of major adverse cardiovascular events (MACE) in individuals with [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604) at low or moderate risk of CVD. Preventive [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25) therapy should be considered in individuals with [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604) even if their risk of CVD is low or moderate.\nStudy breakdown\n- Study population: 7769 participants with well-controlled\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)on [ART](/de/wissen/HIV-Infektion#Z8085d2401472cb7e809cfc2fe50faf6c)at low or moderate risk of cardiovascular disease; [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age 50 years\n- Methods: phase 3 randomized\n[placebo]-controlled trial\n- Main results\n- The trial was terminated early because of proven effectiveness of the intervention.\n- Incidence of muscle-related symptoms and\n[diabetes mellitus](/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261)were higher in the pitavastatin group than the [placebo]group, but discontinuation rate was low.\n- Limitations include: Early termination may have led to underestimation of long-term risks of pitavastatin use.\n- Study funding: National Institutes of Health, Kowa Pharmaceuticals America, Gilead Sciences, ViiV Healthcare\n- Original study: Pitavastatin to prevent cardiovascular disease in\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)infection [16]\n- Related AMBOSS articles:\n[HIV-Infektion](/de/wissen/HIV-Infektion#Z54541a53e014f60bb262be162cea06e7)\nAcute\n[sinusitis](/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02): the color of nasal discharge is snot important\nOne-Minute Telegram 80-2023-2/3\n10-second takeaway\nAntibiotics are often overprescribed for children with upper respiratory tract symptoms and suspected acute\n[sinusitis](/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02). This study demonstrated that antibiotics were more effective than [placebo] in reducing symptoms of acute [sinusitis](/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02), but mainly when nasopharyngeal pathogens (NPP) were present. The effectiveness of antibiotics in reducing symptoms was similar in patients with clear or colored nasal discharge. Point-of-care testing for NPP may help reduce unnecessary antibiotic use.\nStudy breakdown\n- Study population: 515 children aged 2\u201311 (54% male, 52% White, 89% non-Hispanic) meeting established criteria for acute\n[sinusitis](/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02)\n- Methods: randomized clinical trial\n- Subgroups stratifed by presence or\n[absence](/de/wissen/Epileptische_Anf\u00e4lle_und_Epilepsien#Z93dedd171a6efaddb5d27c931860ee21)of green or yellow nasal discharge\n- NPP bacterial cultures obtained at beginning and end of study\n- Randomized 1:1 to a combination of\n[amoxicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Za6dad35eb36b5da0940872cd1193a503)90 mg/kg/day and clavulanate 6.4 mg/kg/day PO or [placebo]\n- Primary outcome: daily symptom burden based on the Pediatric\n[Rhinosinusitis](/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02)Symptoms Scale (PRSS)\n- Subgroups stratifed by presence or\n- Main results\n- Mean PRSS scores were significantly lower in the antibiotic group than in the\n[placebo]group.\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)time to symptom resolution was lower in the antibiotic group (7 days) than in the [placebo]group (9 days).\n- Subgroup analysis\n- Mean PRSS score difference was greatest in the subgroup with culture-proven NPP.\n- Mean PRSS score difference was similar across groups regardless of nasal discharge color.\n- Higher incidence of diarrhea in antibiotic group than in\n[placebo]group: 11.4% vs. 4.7% (RR 2.40; 95% CI, 1.26\u20134.59)\n- Mean PRSS scores were significantly lower in the antibiotic group than in the\n- Limitations include: limited generalizability to children with mild or severe\n[sinusitis](/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02)\n- Patients with severe\n[sinusitis](/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02)were excluded.\n- Study participants had higher PRSS scores than those who declined to participate.\n- Patients with severe\n- Study funding: National Institute of Allergy and Infectious Diseases\n- Original study: Identifying children likely to benefit from antibiotics for acute\n[sinusitis](/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02): a randomized clinical trial [17]\n- Related AMBOSS article:\n[Sinusitis](/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02)\nThe\n[oral] PEN is as mighty as the needle\nOne-Minute Telegram 80-2023-3/3\n10-second takeaway\nFewer than 5% of patients whose medical record is flagged with a\n[penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc) allergy label have a true [penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc) allergy. This study demonstrated that a direct [oral] challenge in patients with a low-risk [penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc) allergy was safe and noninferior to skin testing followed by an [oral] challenge in verifying an actual [penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc) allergy. Direct [oral] [penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc) testing could reduce the burden of proactive [penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc) allergy delabeling and improve antibiotic stewardship.\nStudy breakdown\n- Study population: 377 adults with a reported\n[penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc)allergy in their medical record and a PEN- [FAST]score of < 3\n- Methods: multicenter open-label, randomized clinical trial\n- PEN-\n[FAST]score (range 0\u20135) calculated based on:\n-\n[Penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc)allergy reported\n- \u2264 5 years since reaction (2 points)\n- Angioedema or anaphylaxis OR severe cutaneous adverse reactions (2 points)\n- Treatment required (1 point)\n-\n- Randomized 1:1 to direct\n[oral] [penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc)challenge (intervention) or standard skin testing followed by [oral]challenge if the skin test was negative (control)\n- Primary outcome: immune-mediated reaction within one hour of\n[oral]challenge\n- Secondary outcomes: safety, delabeling possible\n- PEN-\n- Main results\n- The\n[oral] [penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc)challenge was positive in 0.5% of participants in both groups (RR 1.02; 90% CI, 0.10\u201310.34).\n-\n[Adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)within 5 days were similar between groups.\n- The\n[penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc)allergy label was removed from 99.5% of participants records in the intervention group and from 97.9% in the control group.\n- The\n- Limitations include:\n- The majority of patients had a PEN-\n[FAST]score of < 2, limiting generalizability to patients with higher scores.\n- Patients with any history of drug-induced anaphylaxis were excluded, limiting generalizability regarding safety and noninferiority in that population.\n- The majority of patients had a PEN-\n- Study funding: Austin Medical Research Foundation\n- Original study:\n[Efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)of a clinical decision rule to enable direct [oral]challenge in patients with low-risk [penicillin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc)allergy: the PALACE randomized clinical trial [18]\n- Related AMBOSS articles:\n[Arzneimittelallergie](/de/wissen/Allergische_Erkrankungen#Z0075153d2fce0d752858b0566e951c5a)| [Penicilline](/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc)\nEdition 79 - July 29, 2023\nSpill the T:\n[testosterone](/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3) safety in men with CVD\nOne-Minute Telegram 79-2023-1/3\n10-second takeaway\n[Testosterone](/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3) replacement therapy (TRT) is frequently used to treat symptoms of hypogonadism in men, but previous studies have provided conflicting information about its cardiovascular safety. In this large-scale study, TRT in men with preexisting or high risk of cardiovascular disease (CVD) was noninferior to [placebo] for the incidence of major adverse cardiac events (MACE), but was associated with a higher incidence of atrial [fibrillation], [acute kidney injury](/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4), and pulmonary embolism. Because [testosterone](/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3) deficiency is not life-threatening, clinicians should continue to individualize the decision to begin TRT.\nStudy breakdown\n- Study population: 5204 men aged 45\u201380 years with preexisting or a high risk of CVD, symptoms of hypogonadism, and two morning\n[testosterone](/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3)levels < 300 ng/dL\n- Methods: noninferiority, multicenter, randomized, double-blind,\n[placebo]-controlled trial\n- Randomized 1:1 to daily transdermal 1.62%\n[testosterone](/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3)gel (TRT group) or [placebo]gel\n- The\n[testosterone](/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3)dose in the TRT group was adjusted to maintain a [testosterone](/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3)level between 350 and 750 ng/dL.\n- Primary endpoint: first MACE, i.e., death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke\n- Mean duration of treatment: 22 \u00b1 14 months; mean follow-up: 33 \u00b1 12 months\n- Randomized 1:1 to daily transdermal 1.62%\n- Main results\n- TRT was noninferior to\n[placebo]for incidence of MACE: 7.0% in the TRT group vs. 7.3% in the [placebo]group (HR, 0.96; 95% CI, 0.78\u20131.17)\n- The incidence of several adverse effects was higher in the TRT group than the\n[placebo]group.\n- Atrial\n[fibrillation]: 3.5% vs. 2.3%\n-\n[Acute kidney injury](/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4): 2.3% vs. 1.5%\n- Pulmonary embolism: 0.9% vs. 0.5%\n- Atrial\n- TRT was noninferior to\n- Limitations include: Adherence and retention rates were low.\n- Study funding: AbbVie, Acerus Pharmaceuticals, Endo Pharmaceuticals, Upsher-Smith Laboratories\n- Original study: Cardiovascular safety of\n[testosterone](/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3)-replacement therapy [19]\n- Related AMBOSS article:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)| [Testosteronsubstitution](/de/wissen/Hypophysenvorderlappeninsuffizienz#Ze6a5e3f834a264b2ebf8c8fdfe50fa37)\nDoes\n[vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84) supplementation reduce cardiovascular risk?\nOne-Minute Telegram 79-2023-2/3\n10-second takeaway\nLow\n[serum] [vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84) levels are associated with increased risk of cardiovascular disease, but studies to date have not shown that [vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84) supplementation prevents major adverse cardiovascular events (MACE). In this Australian study, 5 years of [vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84) supplementation was associated with a small reduction in the incidence of MACE compared to [placebo], but the absolute risk difference was not significant. Further studies focusing on individuals with high cardiovascular risk may find a clearer role for [vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84) supplementation.\nStudy breakdown\n- Study population: 21,315 participants aged 60\u201384 years with no prior\n[vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)supplementation and no contraindications to [vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)therapy\n- Methods: randomized, double-blind,\n[placebo]-controlled trial\n- Randomized 1:1 to\n[oral] [vitamin D3](/de/wissen/Vitamine#Z3cebeed83653053fef153c67a295db41)60,000 IU/month or [placebo]\n- Main outcome: first MACE, i.e., myocardial infarction, stroke, or coronary revascularization\n- Incidence of MACE was determined using national administrative databases.\n-\n[Serum]25(OH)D concentration was measured yearly in a random subset of participants.\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)treatment duration: 5 years\n- Randomized 1:1 to\n- Main results\n-\n[Vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)group had a slightly lower incidence of MACE than the [placebo]group: HR, 0.91; 95% CI, 0.81\u20131.01 (-5.8 events per 1000 participants)\n- Myocardial infarction: HR, 0.81; 0.67\u20130.98\n- Coronary revascularisation: HR, 0.89; 0.78\u20131.01\n- MACE in subgroup taking cardiovascular drugs: HR, 0.84; 0.74\u20130.97\n- Mean\n[serum]25(OH)D concentration\n-\n- Limitations include:\n-\n[Angina]and myocardial infarction are reported together in the national database, which may have affected the results.\n- The study population had lower\n[statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)usage and a lower smoking rate than the general population, limiting generalizability.\n- The results are not generalizable to populations with a greater prevalence of\n[vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)deficiency.\n-\n- Study funding: National Health and Medical Research Council\n- Original study:\n[Vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)supplementation and major cardiovascular events: D-Health randomised controlled trial [20]\n- Related AMBOSS articles:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)| [Vitamin-D-Mangel](/de/wissen/Vitamine#Zb9215d84319323ec614350131f9e006b)\nRevisiting an old drug for smoking cessation\nOne-Minute Telegram 79-2023-3/3\n10-second takeaway\nCytisinicline has been used successfully as an over-the-counter smoking cessation medication in Europe for over 50 years, but the current 6 times daily dosing regimen limits adherence. In this US study, individuals taking cytisinicline 3 times daily were significantly more likely to have continuous smoking abstinence than those taking\n[placebo]. This effective and well-tolerated medication may provide another option for treating nicotine dependence.\nStudy breakdown\n- Study population: 810 adults who smoked \u2265 10 cigarettes per day (mean age 53 years; 55% female; mean 19 cigarettes smoked daily)\n- Methods: double-blind,\n[placebo]-controlled, randomized trial\n- Randomized 1:1:1\n- All participants received frequent behavioral support.\n- Assessments were conducted weekly from weeks 2 to 12 and at weeks 16, 20, and 24.\n- Abstinence was self-reported and verified by expired CO measurements (\u2264 10 ppm).\n- Main outcomes\n- Continuous smoking abstinence during the last 4 weeks of active treatment\n- Continuous smoking abstinence from the end of treatment through week 24\n- Main results\n- Continuous smoking abstinence rates were significantly higher with cytisinicline than\n[placebo].\n- 6-week course of cytisinicline\n- Weeks 3\u20136: 25.3% vs. 4.4% (OR, 8.0; 95% CI, 3.9\u201316.3)\n- Weeks 3\u201324: 8.9% vs. 2.6% (OR, 3.7; 1.5\u201310.2)\n- 12-week course of cytisinicline\n- Weeks 9\u201312: 32.6% vs. 7.0% (OR, 6.3; 3.7\u201311.6)\n- Weeks 9\u201324: 21.1% vs. 4.8% (OR, 5.3; 2.8\u201311.1)\n- 6-week course of cytisinicline\n- Cytisinicline was well tolerated.\n- Nausea, abnormal dreams, and/or insomnia occurred in < 10% of participants.\n- No serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)occurred.\n- Continuous smoking abstinence rates were significantly higher with cytisinicline than\n- Limitations include:\n- The study population was predominantly White, limiting generalizability to other racial and ethnic groups.\n- Individuals with mental health conditions and/or illicit drug use were excluded.\n- Follow-up was limited to 24 weeks; long-term results are unknown.\n- Study funding: Achieve Life Sciences pharmaceuticals\n- Original study: Cytisinicline for smoking cessation: a randomized clinical trial [21]\n- Related AMBOSS articles:\n[Raucherentw\u00f6hnung](/de/wissen/Rauchen_und_Tabakkonsum#Z59e06ec3054a6b1fa6afa36f59825443)\nEdition 78 - July 15, 2023\nUSPSTF recommends screening adults for major\n[depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473) disorder and anxiety disorders\nOne-Minute Telegram 78-2023-1/3\n10-second takeaway\nMajor\n[depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473) disorder (MDD) and anxiety disorders are common conditions with a potential to profoundly impact the well-being of affected individuals. The United States Preventive Services Task Force (USPSTF) has reaffirmed its previous recommendation to screen all adults for MDD and added a new recommendation to screen adults under 64 years of age for anxiety disorder. There was insufficient evidence to support a recommendation to screen for risk of suicide. Medical providers should use their clinical judgment to determine screening intervals.\nRecommendation breakdown\n- Recommendations\n- The USPSTF concluded with moderate certainty that there is a benefit to screen for MDD in all adults and for anxiety disorders in adults < 64 years.\n- There was insufficient evidence to recommend screening for:\n- Anxiety disorders in adults \u2265 65 years\n- Risk of suicide in adults\n- Applicable population: asymptomatic adults \u2265 19 years, including pregnant and postpartum individuals\n- Additional information\n- Commonly used screening tests for\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)included the Patient Health Questionnaire (PHQ) and Geriatric [Depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)Scale (GDS).\n- Commonly used screening tools for anxiety included versions of the Generalized Anxiety Disorder (GAD) Scale.\n- Commonly used screening tests for\n- Potential harms of screening\n- Treatment of newly diagnosed anxiety disorders may result in addiction and/or misuse of benzodiazepines.\n- Some interventions for elevated risk of suicide may increase the risk for self-harm.\n- Limitations include:\n- There is limited data for recommendations on screening intervals for anxiety disorders and MDD.\n- The recommendations do not apply to\n[depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)disorders other than MDD.\n- Further research is needed on:\n- Screening tools for anxiety disorders in specific populations\n- Benefits of screening for risk of suicide\n- Study funding: The Agency for Healthcare Research and Quality (AHRQ)\n- Original studies\n- Screening for anxiety disorders in adults [22]\n- Screening for\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)and suicide risk in adults [23]\nPromising potential for a once-weekly basal\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) analogue\nOne-Minute Telegram 78-2023-2/3\n10-second takeaway\nDaily basal\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) is often included in the treatment regimen of newly diagnosed type 2 diabetes in order to improve glycemic control, but the requirement of frequent injections may reduce patient adherence and actually worsen control. In this trial, an investigational once-weekly basal [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) analogue ( [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) icodec) produced better glycemic control than once-daily [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) glargine in newly diagnosed type 2 diabetes. New longer-acting basal [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) analogues may improve glycemic control and potentially improve patient adherence by reducing the frequency of injections.\nStudy breakdown\n- Study population: 984 adults \u2265 18 years with type 2 diabetes,\n[HbA1c](/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4)7\u201311%, [BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04)\u2264 40 kg/m2, and no previous history of [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)use\n- Methods\n- International, randomized, open-label, treat-to-target, phase 3a trial (ONWARDS 1)\n- Randomized 1:1 to receive once-weekly\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)icodec (starting dose 70 units per week) or once-daily [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)glargine U100 (starting dose 10 units per day)\n- Dosage was titrated to achieve a prebreakfast blood\n[glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57)level of 80\u2013130 mg/dL.\n- Primary endpoint: change in\n[HbA1c](/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4)from [baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293)to 52 weeks\n- Secondary endpoint: percentage of time spent in target glycemic range of 70\u2013180 mg/dL during weeks 48\u201352\n- Duration: 52-week main phase and 26-week\n[extension](/de/wissen/Terminologie#Zbdfd278a2badf97a52d598dc2cd2c497)\n- Follow-up period: 5 weeks\n- Main results\n- Mean reduction in\n[HbA1c](/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4)was greater in the [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)icodec group than in the glargine U100 group (estimated treatment difference, -0.19 percentage points; 95% CI, -0.36 to -0.03).\n- Percentage of time spent in the target glycemic range was higher in the\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)icodec group than in the glargine U100 group (estimated treatment difference, 4.27 percentage points; 95% CI, 1.92 to 6.62).\n- Participants in the\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)icodec group were more likely to have the following compared to those in the glargine U100 group:\n- Incidence of hypoglycemia and\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)were similar in both groups.\n- Mean reduction in\n- Limitations include:\n- Study funding: Novo Nordisk\n- Original study: Weekly icodec versus daily glargine U100 in type 2 diabetes without previous\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)[24]\nIs bempedoic\n[acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f) an effective alternative for patients with [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25) intolerance?\nOne-Minute Telegram 78-2023-3/3\n10-second takeaway\nStatins are recommended for the primary prevention of major adverse cardiovascular events (MACE), but there are no known effective alternatives for treating at-risk individuals with\n[statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25) intolerance. In this trial, bempedoic [acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f) was shown to reduce the risk of first-time MACE in at-risk patients with [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25) intolerance. Bempedoic [acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f) may be an effective alternative to statins for primary prevention of MACE.\nStudy breakdown\n- Study population: 4206 adults (mean age 68 years) with\n[LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163)-C \u2265 100 mg/dL, high cardiovascular risk, no previous MACE, and a reported [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)intolerance (59% female; 92% White, 3% Black; 66% with diabetes)\n- Methods: international, masked, randomized clinical trial\n- 1:1 randomization to bempedoic\n[acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f)(180 mg PO daily) or [placebo]\n-\n[LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163)-C values were unmasked at month 6 and treatment was adjusted per local protocol if they were \u2265 25% above [baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293).\n- High-sensitivity C-reactive\n[protein](/de/wissen/Aminos\u00e4uren_und_Proteine#Z6760651e0606c30942f14701885fce12)( [hsCRP]) was measured at month 12.\n- Primary endpoint: time to first occurrence of 4-component MACE (death from a cardiovascular cause, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization)\n- Secondary endpoints\n- Time to first occurrence of a 3-component MACE (death from a cardiovascular cause, nonfatal myocardial infarction, nonfatal stroke)\n- Time to first occurrence of a 5-component MACE (death from a cardiovascular cause, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable\n[angina])\n- Other outcomes: all-cause mortality\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)follow-up: 39.9 months\n- 1:1 randomization to bempedoic\n- Main results\n- Risk of MACE was reduced in the bempedoic group vs. the\n[placebo]group\n- 4-component MACE: 5.3% vs. 7.6% (adjusted HR, 0.70; 95% CI, 0.55\u20130.89)\n- 3-component MACE: 4.0% vs. 6.4% (HR, 0.64; 95% CI, 0.48\u20130.84)\n- 5-component MACE: 2.3% vs. 7.8% (HR, 0.69; 95% CI, 0.54\u20130.88)\n- All-cause mortality was lower in the bempedoic group than in the\n[placebo]group.\n-\n[LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163)-C and [hsCRP]levels were lower in the bempedoic [acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f)group than in the [placebo]group.\n- Incidence of serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)and [adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)leading to drug discontinuation were similar between groups.\n- Risk of MACE was reduced in the bempedoic group vs. the\n- Limitations include:\n- The study is a subgroup analysis of a larger trial, which may have caused an increase in false-positive results and wider confidence intervals.\n- The study did not include participants with\n[LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163)-C levels < 100 mg/dL.\n- Study funding: Esperion Therapeutics, Inc.\n- Original study: Bempedoic\n[acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f)for primary prevention of cardiovascular events in [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)-intolerant patients [25]\nEdition 77 - July 1, 2023\nThe drill still fits the bill for chronic\n[SDH](/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602)\nOne-Minute Telegram 77-2023-1/3\n10-second takeaway\nBurr-hole craniostomy is the current standard of care for symptomatic chronic subdural hematoma (\n[SDH](/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602)), but noncontrolled studies have suggested that [glucocorticoid](/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151) therapy may be an effective alternative. In this trial, patients with symptomatic chronic [SDH](/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602) treated with standalone dexamethasone had worse outcomes and more complications than patients treated with surgery.\nStudy breakdown\n- Study population: 252 adults (mean age 74 years; 77.4% men) with a new diagnosis of symptomatic chronic\n[SDH](/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602)verified by [CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f)scan\n- Methods: multicenter, open-label, controlled noninferiority trial in the Netherlands\n- Randomized 1:1 to 19-day taper of\n[oral]or IV dexamethasone (n = 127) vs. burr-hole evacuation with subdural drain (n = 125)\n- Dexamethasone was discontinued and surgery was offered if participants did not show functional improvement at 2 weeks or had worsening symptoms, severe adverse effects, or hematoma expansion.\n- Primary endpoint: functional outcome at 3 months (modified Rankin scale)\n- Secondary endpoints: additional therapy received, length of hospitalization,\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)\n- Randomized 1:1 to 19-day taper of\n- Main results\n- The trial was terminated prematurely because of poor outcomes and\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)in the dexamethasone group.\n- Dexamethasone did not meet noninferiority criteria: adjusted OR, 0.55 (95% CI, 0.34\u20130.90) for better functional outcomes compared with surgery\n- Compared with the surgery group, the dexamethasone group:\n- Received more additional therapies (61% vs.17%)\n- Had longer mean hospitalizations (12 days vs. 7 days)\n- Had more\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c): infection (23% vs.19%), hyperglycemia (20% vs. 4%), [delirium](/de/wissen/Delir#Zcc15b4e469e0fd3a6d1aac118f7b59b5)(16% vs. 6%)\n- The trial was terminated prematurely because of poor outcomes and\n- Limitations include:\n- Open-label design and local practice patterns may have influenced the decision to perform surgery on patients in the dexamethasone group.\n- Results may not be generalizable: Only \u223c 25% of screened patients with\n[SDH](/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602)were enrolled.\n- Most patients had mild symptoms.\n- Multiple exclusion criteria (e.g., coma, lack of symptoms,\n[HbA1c](/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4)> 8%)\n- The dexamethasone group had worse functional impairment at\n[baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293), which may have contributed to negative outcomes.\n- Study funding: Netherlands Organization for Health Research and Development; Jacobus Foundation, the Hague; and Erasmus Medical Center\n- Original study: Dexamethasone versus surgery for chronic subdural hematoma [26]\n- Related AMBOSS article:\n[Subdurales H\u00e4matom](/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602)\nDOACs safe and effective in cancer-associated VTE\nOne-Minute Telegram 77-2023-2/3\n10-second takeaway\nCurrent guidelines recommend the use of\n[low molecular weight heparin](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a) ( [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a)) to prevent recurrent venous thromboembolism (VTE) in patients with cancer. This trial demonstrated that direct [oral] anticoagulants (DOACs) were noninferior to [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a) in the prevention of recurrent VTE in patients with cancer. DOACs are likely a safe and convenient alternative to [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a) for patients with cancer-associated VTE.\nStudy breakdown\n- Study population: 671 adults with cancer and a recently diagnosed VTE\n- Methods: multicenter, randomized, nonblinded pragmatic effectiveness study\n- Randomized 1:1 to a\n[DOAC](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721)(n = 335) or [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a)(n = 336) for 6 months\n- Specific agents were chosen based on individual patient factors and availability.\n- Primary outcome: cumulative recurrence of nonfatal VTE at 6 months\n- Other outcomes: bleeding, death, health-related quality of life, patient perception of anticoagulation therapy, serious and severe\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c), adherence\n- Randomized 1:1 to a\n- Main results\n- No significant difference in recurrent VTE rate in the\n[DOAC](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721)group (6.1%) vs. the [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a)group (8.8%): difference less than the predefined 3% noninferiority margin\n- Agents received\n-\n[DOAC](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721)group: 58% [apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911), 37% [rivaroxaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z22bbeb78e62fcd17cbdcc573e8ff87cd), 3% [dabigatran](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zf1157dfb62b05f3e741ccd036588d15f), 2% [edoxaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z5c892255c4fb7d1881dd4e503d8aad18)\n-\n[LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a)group: 90% [enoxaparin](/de/wissen/Nicht-orale_Antikoagulation#Zec68de4bb7f82a9ac0b38e5ae9bf260f), 7% [fondaparinux](/de/wissen/Nicht-orale_Antikoagulation#Ze7e718cee0977fa4f04b6436e836e8e8), 3% [dalteparin](/de/wissen/Nicht-orale_Antikoagulation#Z64059939414d9e0325d9fd1e8fcd40ec)\n- No significant difference in major bleeding, death, or patient-reported outcomes\n- Higher adherence in the\n[DOAC](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721)group at 6 months (71% vs. 59%)\n- No significant difference in recurrent VTE rate in the\n- Limitations include:\n- Study funding: Patient-Centered Outcomes Research Institute\n- Original study: Direct\n[oral]anticoagulants vs low-molecular-weight [heparin](/de/wissen/Nicht-orale_Antikoagulation#Zad69ea8aed3a6bbd4fda7fc9c0572707)and recurrent VTE in patients with cancer: a randomized clinical trial [27]\n- Related AMBOSS article:\n[Tiefe Beinvenenthrombose](/de/wissen/Phlebothrombose#Z28ca7507422e8791c7b034c316a126e1)\n[Nitro](/de/wissen/Nitrate_und_Molsidomin#Z297e68c91e1cac660e7d5df4acb11c80) patch is no match for the hot flash\nOne-Minute Telegram 77-2023-3/3\n10-second takeaway\nConcern about the safety of long-term\n[hormone](/de/wissen/Allgemeine_Endokrinologie#Z5f7d7972b934850e5dc5e2efdb60e476) therapy for perimenopausal symptoms has led to increased interest in nonhormonal treatments for hot flashes. In this study, continuous transdermal [nitroglycerin](/de/wissen/Nitrate_und_Molsidomin#Z297e68c91e1cac660e7d5df4acb11c80) (NTG) therapy did not significantly decrease the frequency or severity of hot flashes compared to [placebo]. Further research into other approaches to reducing perimenopausal vasomotor symptoms is needed.\nStudy breakdown\n- Study population: 141 perimenopausal and\n[postmenopausal](/de/wissen/Klimakterium#Zac4b020fde98661beb72a24ef0b8c067)women (age range 40\u201362 years) with \u2265 7 hot flashes per day who were not receiving other medications with potential [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)for hot flashes\n- Methods: single-center, double-blinded,\n[placebo]-controlled [RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28)\n- Randomized 1:1 to uninterrupted transdermal NTG (0.2\u20130.6 mg/hour daily; n = 70) vs.\n[placebo]patch (n = 71) for 12 weeks\n- Primary outcome: change in frequency of hot flashes at 5 and 12 weeks\n- Other outcomes: change in frequency of moderate to severe hot flashes, hot flash severity, impact on function and quality of life, safety (headaches, chest pain, syncope, blood pressure)\n- Randomized 1:1 to uninterrupted transdermal NTG (0.2\u20130.6 mg/hour daily; n = 70) vs.\n- Main results\n- No significant difference in primary outcome between groups\n- Both groups reported a reduction in frequency of all hot flashes and moderate to severe hot flashes.\n- The NTG subgroup in late\n[perimenopause](/de/wissen/Klimakterium#Z3338447bd98233f0307b8f0cd29395a1)had a reduction in moderate to severe hot flash frequency compared to [placebo](difference -3.0 episodes per day; 95% CI, -5.2 to -0.2).\n- Significantly more headaches with NTG at 1 week (66% vs. 6%) but not at 12 weeks (1.4% vs. 1.4%)\n- Limitations include:\n- Higher rate of medication discontinuation in the NTG group (20% vs. 7%)\n- Racial heterogeneity: more Black participants in the NTG group (17% vs. 6%)\n- Study funding: National Institutes of Health\n- Original study:\n[Efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)of continuous transdermal [nitroglycerin](/de/wissen/Nitrate_und_Molsidomin#Z297e68c91e1cac660e7d5df4acb11c80)for treating hot flashes by inducing [nitrate](/de/wissen/Nitrate_und_Molsidomin#Zc7d2c406d565ba6a80254c5045509ae7)cross-tolerance in perimenopausal and [postmenopausal](/de/wissen/Klimakterium#Zac4b020fde98661beb72a24ef0b8c067)women: a randomized clinical trial [28]\n- Related AMBOSS article:\n[Menopause](/de/wissen/Klimakterium#Z6968f8f221cf989eebc438d5fde47c8e)\nQ2 2023\n-\n[One-Minute Telegram 76-2023](/de/wissen/One-Minute_Telegram_Archiv#Zddb9aef2b3a93bc9df1e95b94b1f96c5)\n- Missed opportunities in the treatment of OUD\n- Hypertrophic hearts can still flex\n- Stalled progress on reducing excess mortality in the Black population\n-\n[One-Minute Telegram 75-2023](/de/wissen/One-Minute_Telegram_Archiv#Z6fff29d49dee9a62e43a4cb98d13bf30)\n-\n[One-Minute Telegram 74-2023](/de/wissen/One-Minute_Telegram_Archiv#Z440d447048754ea13f8bedfdec8fa4c1)\n- Unclear benefit of skin cancer screening\n- Respect the decision to resect\n- A guide for heart failure guidelines\n-\n[One-Minute Telegram 73-2023](/de/wissen/One-Minute_Telegram_Archiv#Z107c60c7a1629f12f4f41ada741592fa)\n- The high price of\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)costs\n- Providing a boost for treatment-resistant\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)\n- The financial penalty on being a female physician\n- The high price of\n-\n[One-Minute Telegram 72-2023](/de/wissen/One-Minute_Telegram_Archiv#Z97a0ccbec6c29b6691a28d0fc581bfc4)\nEdition 76 - June 3, 2023\nMissed opportunities in the treatment of OUD\nOne-Minute Telegram 76-2023-1/3\n10-second takeaway\nMortality related to\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) use disorder (OUD) is increasing rapidly in the United States, particularly in the Black population. In this study, Black patients were substantially less likely to receive outpatient pharmacological intervention for OUD than White patients. Addressing racial and ethnic disparities in the treatment of OUD is necessary to successfully combat the national [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) overdose epidemic.\nStudy breakdown\n- Study population: 23,370 adults receiving Medicare as a result of disability who experienced at least one OUD-related index event (15% Black, 8% Hispanic, 77% White)\n- Methods: retrospective cohort study using Medicare claims data from 2016 to 2019\n- OUD-related index events included:\n- Emergency department or inpatient treatment for a nonfatal overdose\n- Hospitalization with an injection drug use-related infection\n- Admission to an OUD\n[rehabilitation](/de/wissen/Rehabilitation#Z14f5cd16659409413ce2eea2b5ab7e2e)facility or detoxification unit\n- Patients with long-term\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)prescriptions and those receiving end-of-life care were excluded.\n- Primary outcome: receipt of buprenorphine, naltrexone, or naloxone within 180 days of an OUD index event\n- Secondary outcomes: contact with a health care provider within 180 days of an index event\n- OUD-related index events included:\n- Main results\n- Black individuals (12.7%) were less likely to receive buprenorphine following an OUD event than Hispanic (18.7%) or White individuals (23.3%).\n- Black individuals (14.4%) were less likely to receive naloxone following an OUD event than Hispanic (20.7%) or White individuals (22.9%).\n- Naltrexone receipt was low overall and did not differ between groups.\n- Racial differences in receipt of medications did not change significantly from 2016 to 2019.\n- Disparities in opportunities to receive medication after an OUD event were minor (mean number of ambulatory visits within 180 days: 6.6 for Black patients, 6.7 for Hispanic patients, and 7.6 for White patients).\n- Limitations include:\n- Receipt of methadone following an OUD event was not included in the study, which may have led to\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1).\n- Claims data only reflects prescriptions that were filled.\n- The study only included Medicare beneficiaries with disabilities and therefore may not be generalizable to other populations.\n- Receipt of methadone following an OUD event was not included in the study, which may have led to\n- Study funding: National Institute on Drug Abuse, National Institute on Aging\n- Original study: Racial inequality in receipt of medications for\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)use disorder [29]\n- Related AMBOSS articles:\n[Opioidabh\u00e4ngigkeit](/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z9f4a33561601fe529f3c7dfbe30ba130)| [Opioid-Intoxikation](/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z76aa6b4f42cf89c1f5aca166ccf1f874)| [Opioidentw\u00f6hnung](/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Zaf6487b8c4af3cde01aecd4c7a7d2e26)\nHypertrophic hearts can still flex\nOne-Minute Telegram 76-2023-2/3\n10-second takeaway\nHealth care providers often instruct patients with hypertrophic cardiomyopathy (\n[HCM](/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46)) to avoid vigorous exercise to reduce the risk of [sudden cardiac death], but evidence for this recommendation is lacking. In this study, patients with [HCM](/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46) who exercised vigorously on a regular basis were no more likely to experience [sudden cardiac death] or a life-threatening arrhythmia than those who engaged in moderate exercise or were sedentary. Shared decision-making should be used to determine the appropriate activity level for patients with [HCM](/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46), balancing the low risk of [sudden cardiac death] with the overall benefits of an active lifestyle.\nStudy breakdown\n- Study population: 1660 individuals with\n[HCM](/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46)(either phenotype positive, or phenotype negative and genotype positive) aged 8\u201360 years (mean age 39 years; 60% male) who were able to exercise\n- Methods: investigator-initiated, international, multicenter, prospective, observational cohort study\n- Patients were recruited from high-volume\n[HCM](/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46)centers or self-enrolled\n- Exposure: self-reported activity levels (based on a validated online questionnaire)\n- Outcome: composite endpoint of death, resuscitated sudden cardiac arrest, syncope due to arrhythmia, and appropriate implantable cardioverter defibrillator shocks (based on medical record data)\n- Follow-up period: 3 years\n- Patients were recruited from high-volume\n- Main results\n- 4.6% of participants experienced the composite endpoint\n- No significant difference between rates of the composite endpoint in participants engaging in vigorous exercise (4.7%) and those engaging in nonvigorous (moderate or sedentary) activity (4.6%): adjusted HR, 1.01; 95% one-sided CI, 1.48 (below prespecified boundary of 1.5 for noninferiority)\n- Results were similar in a post hoc analysis including only phenotype-positive patients.\n- Limitations include:\n- Study funding: National Heart, Lung, and Blood Institute\n- Original study: Vigorous exercise in patients with hypertrophic cardiomyopathy [30]\n- Related AMBOSS article:\n[Hypertrophe Kardiomyopathie](/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46)\nStalled progress on reducing excess mortality in the Black population\nOne-Minute Telegram 76-2023-3/3\n10-second takeaway\nIn the United States, the mortality rate in the Black population has exceeded that in the White population for over a hundred years. In this study, it was found that the excess mortality rate in Black individuals declined after 1999, but the rate plateaued in Black men in 2011 and in Black women in 2016 before sharply increasing in 2020, coinciding with the beginning of the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) pandemic. Evidence of ongoing racial disparity in mortality rates should prompt health care providers and policymakers to implement changes to reduce the millions of excess years of life lost in the Black population in the United States.\nStudy breakdown\n- Study population: non-Hispanic Black (denoted as Black) individuals and non-Hispanic White (denoted as White) individuals in the\n[Centers for Disease Control and Prevention]Wide-ranging ONline Data for Epidemiological Research ( [CDC]WONDER) database\n- Methods: serial cross-sectional study\n- Study period: 1999\u20132020\n- Annual number of deaths, population size, and age-adjusted mortality rate per 100,000 individuals by race, age, and sex were obtained from\n[CDC]WONDER death certificate data.\n- Annual life expectancy in 5-year age groups was obtained from the National Center for Health Statistics life tables.\n- Yearly all-cause excess age-adjusted mortality rate in the Black population was calculated by subtracting each year\u2019s age-adjusted mortality rate for White individuals from that for Black individuals.\n- Excess deaths in the Black population was estimated by comparing the number of deaths in the Black population to that in the White population, adjusting for differences in population size.\n- Annual years of potential life lost in the Black population was estimated by using life expectancy data for the White population as the reference for each 5-year age group.\n- Main results\n- Excess mortality rate per 100,000 individuals in the Black male population compared to the White male population\n- 1999\u20132011: decreased from 404 to 211 (P < 0.001)\n- 2012\u20132019: plateaued\n- 2020: increased to 395\n- Excess mortality rate per 100,000 individuals in the Black female population compared to the White female population\n- 1999\u20132015: decreased from 224 to 87 (P < 0.001)\n- 2016\u20132019: plateaued\n- 2020: increased to 192\n- Over the 22-year study period:\n- There were > 1.63 million excess deaths, representing > 80 million excess years of life lost in the Black population compared to the White population.\n- Highest excess mortality rate was due to heart disease\n- Excess mortality rate per 100,000 individuals in the Black male population compared to the White male population\n- Limitations include:\n- The study was based on death certificate data, which is known to contain inaccuracies in reporting of ethnicity, race, and cause of death.\n- Disparities among individuals \u2265 85 years of age were not calculated because neither mortality rates nor population estimates for this subgroup are included in the\n[CDC]WONDER database.\n- Study funding: None\n- Original study: Excess mortality and years of potential life lost among the Black population in the US, 1999\u20132020 [31]\n- Related AMBOSS article:\n[Bias, Stereotype und Diskriminierung in der Medizin - Ethnische Herkunft](/de/wissen/Bias,_Stereotype_und_Diskriminierung_in_der_Medizin#Ze3e07d0fda6b5929e2c15428d82c79e3)\nEdition 75 - May 20, 2023\nContrast-enhanced\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f) to evaluate abdominal pain\nOne-Minute Telegram 75-2023-1/3\n10-second takeaway\nContrast-enhanced\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f) (CECT) is the preferred modality for evaluation of acute abdominal pain in the emergency department (ED). However, unenhanced [CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f) is used in patients with contraindications to contrast (e.g., [renal](/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f) impairment, hypersensitivity). This study found unenhanced [CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f) to be significantly inferior to CECT in ED diagnosis of patients with acute abdominal pain. Contraindications to contrast should be weighed carefully against the diagnostic benefits of [CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f) with contrast.\nStudy breakdown\n- Study population: 201 consecutive patients \u2265 18 years of age (mean age 50 years; 54% female; mean\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04)25.5) who had undergone dual-energy CECT (with [oral]and IV contrast) of the abdomen and pelvis in a single ED for the evaluation of acute abdominal pain\n- Methods: multicenter, retrospective diagnostic accuracy study\n- CECT reference interpretation was established by 3 radiologists.\n- Contrast was digitally subtracted to produce unenhanced\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f)images.\n- Unenhanced\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f)images were interpreted by 6 radiologists (1 faculty and 1 resident from 3 institutions) who were blinded to the reference CECT.\n- Primary outcome: diagnostic accuracy of unenhanced\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f)for the primary cause of abdominal pain\n- Secondary outcome: diagnostic accuracy of unenhanced\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f)for clinically significant incidental findings\n- Main results\n- Unenhanced\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f)was approximately 30% less accurate in identifying both the primary cause of abdominal pain and clinically significant incidental findings.\n- Overall diagnostic accuracy of faculty and residents was similar.\n- Overall diagnostic accuracy was slightly lower in older patients but was not affected by gender or\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04).\n- Unenhanced\n- Limitations include:\n- Retrospective design evaluating imaging with contrast digitally subtracted rather than actual non-contrast-enhanced imaging.\n- The study did not evaluate the diagnostic accuracy of\n[oral]contrast-enhanced studies, which are less commonly avoided than IV contrast-enhanced studies.\n- Study funding: Michigan Institute for Clinical and Health Research\n- Original study: Diagnostic accuracy of unenhanced computed tomography for evaluation of acute abdominal pain in the emergency department [32]\n- Related AMBOSS article:\n[Akutes Abdomen](/de/wissen/Akutes_Abdomen#Z65fa78006dffd500e2e8d5d58969a49e)\nContinue screening at-risk individuals for\n[LTBI](/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94)\nOne-Minute Telegram 75-2023-2/3\n10-second takeaway\nUp to 13 million individuals living in the US have latent tuberculosis infection (\n[LTBI](/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94)). Identification and treatment of [LTBI](/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94) are crucial in preventing the development of active TB and consequent transmissibility, morbidity, and death. The United States Preventive Services Task Force (USPSTF) has reaffirmed its 2016 recommendation to screen for [LTBI](/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94) in adults at risk for infection. Medical providers should use clinical judgment to determine screening intervals.\nRecommendation breakdown\n- Recommendation: The USPSTF concluded with moderate certainty that there is a benefit to screening for\n[LTBI](/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94)in adults at risk for infection.\n- Applicable population\n- Asymptomatic adults \u2265 18 years of age at increased risk for TB infection\n- Risk factors for infection include having lived in:\n- Countries with high TB prevalence\n- Crowded living spaces (e.g., homeless shelters, prisons)\n- Additional information\n- This recommendation does not apply to:\n- Children and adolescents\n- Symptomatic individuals\n- Individuals who receive screening as standard of care (i.e., those with a history of immunosuppression, those who work in high-risk environments)\n- Individuals exposed to a person with active TB\n- Screening is performed by either tuberculin skin test (TST) or\n[interferon](/de/wissen/Gewebshormone#Z3927d9201d2949947fe08525f6ee490e)-gamma release assay ( [IGRA](/de/wissen/Tuberkulose#Z7a6f014a08471d76c8dd62b7588d70ad)).\n- Both tests have moderate sensitivity and high specificity for\n[LTBI](/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94).\n- This recommendation does not apply to:\n- Limitations include:\n- The USPSTF did not find sufficient evidence to provide recommendations on screening frequency.\n- Available data comparing the outcomes of screened vs. unscreened individuals is limited.\n- Study funding: Agency for Healthcare Research and Quality (AHRQ)\n- Original study: Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement [33]\n- Related AMBOSS article:\n[Tuberkulose](/de/wissen/Tuberkulose#Z0db057dcc7fab732110ea50e1288c24c)\nEat, sleep, console, repeat\nOne-Minute Telegram 75-2023-3/3\n10-second takeaway\nStandard management of neonatal abstinence\n[syndrome] may lead to unnecessary use of [opioids](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) and long hospital stays. In this trial, infants managed with a function-based assessment and prioritization of nonpharmacological interventions (the Eat, Sleep, Console approach) were less likely to receive [opioids](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) and were discharged from the hospital earlier than infants managed with standard care, while safety outcomes were similar. The Eat, Sleep, Console approach for neonatal [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) withdrawal [syndrome] shows promise, but further research on long-term outcomes is needed.\nStudy breakdown\n- Study population: 1305 infants with neonatal\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)withdrawal [syndrome]born at \u2265 36 weeks [gestation](/de/wissen/Schwangerschaft#Z7f4a9cfdb95d7dc39e711175bded479e)\n- Methods: multicenter, cluster-randomized, controlled trial at 26 hospitals\n- Randomization of hospitals to 1 of 8 blocks that were each randomly assigned a 3-month time period to transition from usual care to console care\n- At each site, infants were enrolled before and after (but not during) the transitional period.\n- Primary outcome: time from birth to being medically ready for discharge\n- Secondary outcomes: use of pharmacological treatment, duration of hospitalization\n- Safety outcomes from discharge to 3 months of age: in-hospital safety, unscheduled health care visits, nonaccidental trauma, and death\n- Main results\n- 837 infants met readiness for discharge.\n- Compared to the usual-care time period, infants treated during the console-care time period were:\n- Medically ready for discharge earlier (8.2 days vs. 14.9 days; 95% CI, 4.7\u20138.8)\n- Less likely to receive\n[opioids](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)(19.5% vs. 52%; relative risk, 0.38; 95% CI, 0.30\u20130.47)\n- Safety outcomes for infants managed before, during, and after the transitional period were similar.\n- Limitations include:\n- Long-term follow-up data is not available (to date).\n-\n[Confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1)temporal trends (e.g., earlier newborn discharge during the [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)pandemic)\n- Study funding: National Institutes of Health\n- Original study: Eat, Sleep, Console approach or usual care for neonatal\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)withdrawal [34]\n- Related AMBOSS article:\n[Opioidentzugsbehandlung](/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Zaf6487b8c4af3cde01aecd4c7a7d2e26)\nEdition 74 - May 6, 2023\nUnclear benefit of skin cancer screening\nOne-Minute Telegram 74-2023-1/3\n10-second takeaway\nSkin cancer is the most common type of cancer in the US, but it seldom causes serious health problems or death. Melanoma, which has the highest skin cancer mortality rate, constitutes only 1% of skin cancers. The United States Preventive Services Task Force (USPSTF) has reaffirmed its 2016 statement that there is insufficient evidence to determine the balance of benefits and harms with regard to skin cancer screening in asymptomatic adolescents and adults. Medical providers should use their clinical judgment to determine if and when to screen asymptomatic individuals for skin cancer.\nRecommendation breakdown\n- Recommendation: The USPSTF concluded that the current evidence is insufficient to determine the balance of benefits and harms of visual skin examination to screen for skin cancer in adolescents and adults.\n- Applicable population: adolescents and adults with no history of malignant or premalignant skin lesions, no current suspicious lesions, and no increased risk for skin cancer\n- Additional information\n- Visual skin examination is performed by the naked eye or with a dermatoscope.\n- Sensitivity for detecting melanoma is 40\u201370% and specificity is 86\u201398%.\n- Accuracy in detecting keratinocyte carcinoma (i.e., basal or squamous cell carcinoma) is unknown.\n- Available data on the effect of skin cancer screening on early cancer detection and/or mortality is limited and inconsistent.\n- Potential harms of skin cancer screening include adverse psychological effects (e.g., anxiety) and poor cosmetic outcomes following biopsy.\n- This recommendation does not apply to:\n- Individuals with a history of premalignant or malignant skin lesions or those presenting with a lesion suspicious for skin cancer\n- Individuals with a high risk of skin cancer, e.g., those with familial atypical multiple mole and melanoma (FAMMM)\n[syndrome]\n- Visual skin examination is performed by the naked eye or with a dermatoscope.\n- Limitations include:\n- The USPSTF recommendation does not address skin self-exams and self-referral to dermatology, practices which are encouraged by the American Academy of Dermatology.\n- Study funding: Agency for Healthcare Research and Quality (AHRQ)\n- Original study: Screening for skin cancer: US Preventive Services Task Force recommendation statement [35]\n- Related AMBOSS articles:\n[Melanom](/de/wissen/Malignes_Melanom#Z2ffa13415b57f2d7199ba915fda3575a)| [Plattenepithelkarzinom der Haut](/de/wissen/Plattenepithelkarzinom_der_Haut#Zb0726dcdbb4473b05786feb78ac85bd4)| [Basalzellkarzinom](/de/wissen/Basalzellkarzinom#Z1ec5254615034273183546334da2c821)\nRespect the decision to resect\nOne-Minute Telegram 74-2023-2/3\n10-second takeaway\nGuidelines used to inform decision-making on conservative versus surgical management of diverticulitis have relied heavily on retrospective and nonrandomized studies. In this prespecified 2-year follow-up of a randomized clinical trial, elective\n[sigmoid](/de/wissen/Z\u00e4kum_und_Kolon#Zf16ce71b7846680d613611ebb4f1a33d) resection was associated with fewer recurrences of diverticulitis and improved quality of life compared to conservative management in patients with complicated, recurrent, or persistent painful diverticulitis. Early elective [sigmoid](/de/wissen/Z\u00e4kum_und_Kolon#Zf16ce71b7846680d613611ebb4f1a33d) resection may be a good option for patients with diverticulitis, especially when conservative management does not adequately control symptoms.\nStudy breakdown\n- Study population: 90 adults in Finland with recurrent, complicated, or persistent painful diverticulitis (mean age 54 years, 69% women)\n- Methods: multicenter, parallel-group, open-label, individually randomized clinical trial\n- 1:1 randomization to elective laparoscopic\n[sigmoid](/de/wissen/Z\u00e4kum_und_Kolon#Zf16ce71b7846680d613611ebb4f1a33d)resection vs. conservative treatment\n- Surgical group had surgery scheduled within 3 months, followed by dietary counseling.\n- Conservative treatment group received dietary counseling and fiber supplementation for at least 6 months and could receive elective surgery from 6 months after randomization.\n- Outcomes:\n[gastrointestinal](/de/wissen/\u00dcbersicht_des_Verdauungssystems#Zaa3f0692fb4127b17e934892e975ec10)quality of life index (GIQLI) scores at 12 and 24 months, recurrence and severity of diverticulitis, complications\n- 1:1 randomization to elective laparoscopic\n- Main results\n- Compared to the conservative treatment group, the surgery group had:\n- Modestly higher GIQLI scores at 12 months but not at 24 months (\n[intention-to-treat](/de/wissen/Studientypen_der_medizinischen_Forschung#Z12db0a61af1774ca03f632559492fe19)analysis)\n- Significantly lower rates of recurrent diverticulitis at 24 months (11% vs. 61%)\n- Higher rates of postoperative complications at 24 months (10% vs. 5%)\n- Modestly higher GIQLI scores at 12 months but not at 24 months (\n- 18% of patients in the conservative treatment group had surgery within 24 months.\n- Compared to the conservative treatment group, the surgery group had:\n- Limitations include:\n- Small sample size due to early termination for benefit based on prespecified criteria\n- Significant crossover between the groups may have influenced the\n[intention-to-treat](/de/wissen/Studientypen_der_medizinischen_Forschung#Z12db0a61af1774ca03f632559492fe19)results.\n- Analysis was based on a 2-year follow-up date. Longer-term follow-up results are not yet available.\n- Study funding: Vatsatautien Tutkimuss\u00e4\u00e4ti\u00f6 Foundation, Mary and Georg Ehrnrooth\u2019s Foundation, Martti I. Turunen Foundation, the Finnish Medical Foundation, and Helsinki University Hospital research funds\n- Original study: Quality-of-life and recurrence outcomes following laparoscopic elective\n[sigmoid](/de/wissen/Z\u00e4kum_und_Kolon#Zf16ce71b7846680d613611ebb4f1a33d)resection vs conservative treatment following diverticulitis: prespecified 2-year analysis of the LASER randomized clinical trial [36]\n- Related AMBOSS articles:\n[Divertikulitis](/de/wissen/Divertikulose,_Divertikelkrankheit_und_Divertikulitis#Zef9b81a8be3a2511a46e79e9e075b8c7)\nA guide for heart failure guidelines\nOne-Minute Telegram 74-2023-3/3\n10-second takeaway\nGuideline-directed medical therapy (GDMT) has been shown to reduce the risk of death in patients with heart failure with reduced ejection fraction (\n[HFrEF](/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0)), but its implementation in clinical practice has been slow. In this retrospective validation study, a computable medication optimization algorithm (CMOA) accurately identified patients with [HFrEF](/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0) eligible for GDMT initiation or uptitration. Inclusion of computable algorithms into clinical decision support systems can alert clinicians to opportunities for medication optimization and may lead to improved outcomes in patients with [HFrEF](/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0).\nStudy breakdown\n- Study population: patients participating in 2 clinical trials for the treatment of\n[HFrEF](/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0)\n- Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) trial: 841 adults (mean age 61 years, 31% women, 56% White)\n- Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (\n[HF](/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4)-ACTION): 2130 adults (mean age 58 years, 28% women, 62% White)\n- Methods: retrospective validation of a CMOA using clinical data from prior studies\n- A CMOA was created using existing guideline recommendations and then coded into a computerized format.\n- The CMOA was applied retrospectively to individual participants in the previously published GUIDE-IT and\n[HF](/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4)-ACTION studies.\n- Each drug class used in GDMT of\n[HFrEF](/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0)was evaluated for initiation or dosage modification by the CMOA.\n-\n[Angiotensin-converting enzyme](/de/wissen/Nierendurchblutung_und_glomerul\u00e4re_Filtration#Ze2ec510bc7d269d804f7dbd8f36661ab)inhibitor (ACEI)\n- Angiotensin receptor blocker (\n[ARB](/de/wissen/RAAS-Inhibitoren#Zd6e8a87204059b03487185fade42af31))\n- Beta blocker (BB)\n-\n[Mineralocorticoid](/de/wissen/Nebenniere#Z677ca6e3187a3c17aa608668dbb243eb)receptor antagonist (MRA)\n-\n- Recommendations generated by the CMOA were compared to actual medication regimen changes documented during study visits.\n- A CMOA-generated medication optimization score (MOS) at each visit was used to quantify GDMT optimization by study clinicians.\n- Main results\n- Overall, the CMOA identified the need for GDMT optimization in 73% of patients.\n- CMOA identified multiple missed opportunities for GDMT optimization during GUIDE-IT visits.\n- Higher\n[baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293)MOS was associated with lower risk of death or hospitalization.\n- GUIDE-IT: lower risk of cardiovascular death and hospitalization for heart failure (HR, 0.41; 95% CI, 0.21\u20130.80)\n-\n[HF](/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4)-ACTION: lower all-cause death and hospitalization (0.61; 0.44\u20130.84)\n- Limitations include:\n- Results based on clinical trial data may not be generalizable to data collected with typical electronic medical record systems.\n- Some patients were excluded from analysis because follow-up data was not available.\n- Recent guidelines that include newer agents for\n[HFrEF](/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0)were not incorporated into the algorithm.\n- Study funding: Agency for Health Research and Quality, National Institutes of Health, American Health Association Health IT Strategically Focused Research Network, Veterans Affairs\n- Original study: A computable algorithm for medication optimization in heart failure with reduced ejection fraction [37]\n- Related AMBOSS article:\n[Herzinsuffizienz](/de/wissen/Herzinsuffizienz#Z6df09d54c6c264a5c6e2889576ba3477)\nEdition 73 - April 22, 2023\nThe high price of\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) costs\nOne-Minute Telegram 73-2023-1/3\n10-second takeaway\nNonadherence to diabetes medications contributes to adverse outcomes, including inadequate glycemic control and diabetic ketoacidosis. While\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) costs for Medicare beneficiaries were capped by the 2022 Inflation Reduction Act, out-of-pocket expenses remained high for other patients who require [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce). In this study of the prevalence of cost-related [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) rationing, 1 in 5 adults under 65 years of age with diabetes reported rationing. Since the study was conducted, key [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) manufacturers have capped the out-of-pocket cost of [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) at $35 a month, which may improve affordability and reduce [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) rationing.\nStudy breakdown\n- Study population: 495 adults < 65 years of age (mean age 50.7 years) with\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)-treated diabetes\n- 51% women\n- 17% Hispanic, 20% Black, 56% non-Hispanic White\n- Methods: cross-sectional analysis of data from the 2021 National Health Interview Survey (NHIS)\n- Main results\n- Overall, 20.4% (95% CI, 16.2% to 25.3%) reported cost-related\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)rationing.\n- Rationing rates were highest among individuals who were:\n- Black: 26.7% (16% to 41.2%)\n- Middle-income: 30.2% (21.7% to 40.3%)\n- Underinsured or uninsured: 33.7% (25.2% to 43.5%)\n- Overall, 20.4% (95% CI, 16.2% to 25.3%) reported cost-related\n- Limitations include:\n- Use of self-reported data\n- Small sample size\n- Susceptibility to\n[nonresponse](/de/wissen/Pharmakologische_Grundlagen#Z6ae7121c68f777dd7f545ea0bc75299f) [bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0), given the 51% NHIS response rate\n- Study funding: National Institutes of Health\n- Original study: Cost-related\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)rationing in US adults younger than 65 years with diabetes [38]\n- Related AMBOSS articles:\n[Diabetes mellitus](/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261)| [Patientenversorgung und Gesundheitssystem](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z865d37347a16e85f2cb7f1265b6c766b)\nProviding a boost for treatment-resistant\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)\nOne-Minute Telegram 73-2023-2/3\n10-second takeaway\n[Depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473) among older adults is a major health concern with potentially severe consequences. In this trial comparing [augmentation] and switching regimens for older adults with treatment-resistant [depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473), [augmentation] with aripiprazole was the safest and most effective strategy, although overall [remission] rates were low. Augmenting rather than switching medications may be a promising strategy for treatment-resistant [depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473) in this population.\nStudy breakdown\n- Study population: 742 adults \u2265 60 years of age (mean age \u223c 70 years; predominantly female and White) with treatment-resistant\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)\n- Methods: two-step, open-label randomized trial\n- Step 1 (n = 619): randomized 1:1:1 to current antidepressant plus aripiprazole, current antidepressant plus\n[bupropion](/de/wissen/Antidepressiva#Z212f29b4df419c67d6a29424f6b9ebe0), or switching current treatment to [bupropion](/de/wissen/Antidepressiva#Z212f29b4df419c67d6a29424f6b9ebe0)\n- Step 2 (individuals not in\n[remission]after or not eligible for step 1; n = 248): randomized 1:1 to [augmentation]with [lithium](/de/wissen/Lithium#Zc20878d1fde3b53f47307e0a8d3ccbae)or switch to nortriptyline\n- Primary outcome: change in psychological well-being score\n- Secondary outcome:\n[remission]of [depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)\n- Safety outcomes: falls and serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)\n- Follow-up: week 10 after each step\n- Step 1 (n = 619): randomized 1:1:1 to current antidepressant plus aripiprazole, current antidepressant plus\n- Main results: Psychological well-being scores increased across all groups.\n- Step 1: The aripiprazole-\n[augmentation]group had the greatest improvement in well-being scores, highest incidence of [depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473) [remission](29%), and a low reported number of falls. Aripiprazole- [augmentation]was significantly superior to the switch-to- [bupropion](/de/wissen/Antidepressiva#Z212f29b4df419c67d6a29424f6b9ebe0)approach.\n- The\n[bupropion](/de/wissen/Antidepressiva#Z212f29b4df419c67d6a29424f6b9ebe0)- [augmentation]group had the highest rate of falls (0.55 per patient) and injurious falls (0.25 per patient).\n- Step 2: no significant difference between the groups\n- Serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)were similar among all groups.\n- Step 1: The aripiprazole-\n- Limitations include:\n- Lack of participant blinding may have influenced the perceived benefit of receiving two drugs rather than one (performance\n[bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0)).\n- Due to the lack of a control group, the superiority of the tested interventions over continuing the same treatment could not be established.\n- Given the low enrollment rates, the study may have been underpowered to detect differences in effectiveness and safety.\n- Treatment adherence was low, which may have led to an underestimation of treatment\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f).\n- Lack of participant blinding may have influenced the perceived benefit of receiving two drugs rather than one (performance\n- Study funding: Patient-Centered Outcomes Research Institute\n- Original study: Antidepressant\n[augmentation]versus switch in treatment-resistant geriatric [depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)[39]\n- Related AMBOSS article:\n[Unipolare Depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)\nThe financial penalty on being a female physician\nOne-Minute Telegram 73-2023-3/3\n10-second takeaway\nFemale physicians in the US earn significantly less than their male counterparts. In this study of differences in earnings between male and female physicians, female physicians earned less than their male counterparts across all ages and family structures. Marriage with children was associated with the greatest loss of lifetime earnings, primarily because of fewer hours worked. Further work is needed by health leadership to address gender-based earnings disparities.\nStudy breakdown\n- Study population: 95,435 physicians 25\u201364 years of age (mean age 44 years) who responded to the American Community Survey between 2005 and 2019\n- 67.3% White, 19.8% Asian, 4.8% Black, 5.9% Hispanic, 2.2% other\n- 35.8% female\n- Methods: retrospective, cross-sectional study\n- Primary outcomes: annual earned income, hours worked per week, and earnings per hour\n- Differences were measured by:\n- Sex\n- Age\n- Family status: single (i.e., never married, widowed, divorced, or separated), married, and with or without children in the household\n- Main results\n- Compared to male physicians, female physicians:\n- Earned less regardless of age or family structure (average of $194,000 vs. $285,000 per year)\n- Earned 21.4% to 23.9% less per hour\n- No difference in hours worked per week between single female and male physicians\n- Married female physicians worked 7.0% fewer hours (95% CI, 5.6% to 8.4%) than married male physicians.\n- Female physicians with children worked 17.5% fewer hours (16.8% to 18.2%) than male physicians with children.\n- Compared to male physicians, female physicians:\n- Limitations include:\n- The study did not adjust for physician specialty or practice setting.\n- The definition of marriage and whether respondents in other forms of unions were counted as married or single were not clear.\n- Self-reported hours are subject to\n[recall bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Z34d41b30a792b17afcdd32b43ce85f19).\n- Study funding: Gordon and Betty Moor Foundation\n- Original study: Marriage, children, and sex-based differences in physician hours and income [40]\n- Related AMBOSS article:\n[Bias, Stereotype und Diskriminierung in der Medizin](/de/wissen/Bias,_Stereotype_und_Diskriminierung_in_der_Medizin#Zefcdff057a499d78914350d631b15287)\nEdition 72 - April 8, 2023\nAn\n[infusion](/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81) of hope for pneumonia survival\nOne-Minute Telegram 72-2023-1/3\n10-second takeaway\nIn spite of advances in antibiotic therapy and supportive respiratory care, community-acquired pneumonia (CAP) remains the ninth leading cause of death in the US. In this randomized controlled trial, continuous IV hydrocortisone significantly lowered the risk of death in patients with severe CAP compared to\n[placebo]. The early addition of hydrocortisone to the treatment regimen of severe CAP may improve patient outcomes.\nStudy breakdown\n- Study population: 800 adults (\u2265 18 years) admitted to ICUs in France with clinical and radiographic evidence of severe CAP\n- Methods: phase 3, multicenter, double-blind, randomized controlled trial\n- Randomized 1:1 to receive\n[placebo]or a continuous [infusion](/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81)of hydrocortisone 200 mg IV daily started within 24 hours of onset of severity criteria and continued for 4 days, followed by an 8\u201314 day taper regimen\n- All participants received antibiotics and standard supportive care.\n- Primary outcome: death by day 28\n- Secondary outcomes included:\n- Death from any cause within 90 days\n- New requirement for endotracheal\n[intubation](/de/wissen/Allgemeinan\u00e4sthesie#Zea846d3465d1a392fbf008b5131bf900)\n- New requirement for\n[vasopressor]therapy\n- Safety criteria included: secondary infection,\n[gastrointestinal](/de/wissen/\u00dcbersicht_des_Verdauungssystems#Zaa3f0692fb4127b17e934892e975ec10)bleed, daily [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)administration by day 7\n- The trial was conducted prior to the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)pandemic\n- Randomized 1:1 to receive\n- Main results\n- Primary and secondary outcomes: significantly better with hydrocortisone compared to\n[placebo]\n- Death by day 28: 6.2% vs. 11.9% (absolute difference -5.6%; 95% CI, -9.6 to -1.7)\n- Death by 90 days: 9.3% vs. 14.7% (absolute difference, -5.4%; 95% CI, -9.9 to -0.8)\n- New endotracheal\n[intubation](/de/wissen/Allgemeinan\u00e4sthesie#Zea846d3465d1a392fbf008b5131bf900): 18.0% vs. 29.5% (HR, 0.59; 95% CI, 0.40 to 0.86)\n-\n[Vasopressor]administration: 15.3% vs. 25.0% (HR, 0.59; 95% CI, 0.43 to 0.82)\n- Safety outcomes\n- Similar rates of ICU-acquired infections and\n[gastrointestinal](/de/wissen/\u00dcbersicht_des_Verdauungssystems#Zaa3f0692fb4127b17e934892e975ec10)bleeding\n- Higher daily\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)requirements with hydrocortisone than with [placebo]\n- Similar rates of ICU-acquired infections and\n- Primary and secondary outcomes: significantly better with hydrocortisone compared to\n- Limitations include\n- Exclusion of individuals with septic shock\n- Adverse neuromuscular and neuropsychiatric effects were not reported.\n- Bolus dosing of hydrocortisone was not tested.\n- A small number of immunocompromised participants limits generalizability to this population\n- Study funding:\n[French]Ministry of Health\n- Related AMBOSS article:\n[Pneumonie](/de/wissen/Pneumonie#Z00605b3af0c051b1bf6170708112bd0c)\n- Original study: Hydrocortisone in severe community-acquired pneumonia [41]\n[Metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) may defend against osteoarthritis\nOne-Minute Telegram 72-2023-2/3\n10-second takeaway\nOsteoarthritis (OA) is the most common form of arthritis and a major cause of disability in the US. Animal studies suggest\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) may have properties that prevent or modify the progression of OA. This retrospective cohort study found that the use of [metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) for the treatment of diabetes was associated with a significant reduction in the risk of developing OA compared to the use of sulfonylurea. [Metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) may be protective against osteoarthritis, but study limitations currently preclude clinical application.\nStudy breakdown\n- Study population: 41,874 adults aged \u2265 40 years (mean age 62 years) with newly diagnosed type 2 diabetes treated with\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0)or sulfonylurea as monotherapy and no prior history of OA, inflammatory arthritis, or joint replacement\n- 41.8% female\n- 68% White, 13% Black, 13% Hispanic, 4% Asian\n- Methods: retrospective cohort study using data from a large deidentified database in the US.\n- Exposed group: individuals who received\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0)for \u2265 90 days\n- Control group: individuals who received a sulfonylurea for \u2265 90 days\n- Primary endpoint: time to new diagnosis of OA \u2265 90 days after the first prescription fill date\n- Secondary endpoint: time to joint replacement \u2265 90 days after the first prescription fill date\n- Mean duration of treatment: 12 months\n- Exposed group: individuals who received\n- Main results\n- Compared to patients who received sulfonylurea, patients who received\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0)were:\n- 24% less likely to develop OA (aHR, 0.76; 95% CI, 0.68\u20130.85)\n- Equally likely to undergo joint replacement (aHR, 0.80; 95% CI, 0.5\u20131.27)\n- Compared to patients who received sulfonylurea, patients who received\n- Limitations include:\n- Results may have been influenced by unmeasured confounders given the retrospective study design.\n- Potential\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1)factors associated with both [metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0)effect and the risk of developing OA (e.g., lower body mass index) were not included in the analysis.\n- Low numbers of patients using sulfonylureas necessitated using data from patients who had been switched from\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0)to a sulfonylurea in both groups, which may have introduced [bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0).\n- Not generalizable to individuals without diabetes or with type 1 diabetes\n- Study funding: National Institutes of Health, Department of Veterans Affairs Merit Award, and Population Health Sciences Data Core\n- Related AMBOSS Article:\n[Arthrose](/de/wissen/Arthrose#Z02ddc3c6fe4fae13fc187533ee2e65ba)| [Metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0)\n- Original study: Development of osteoarthritis in adults with type 2 diabetes treated with\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0)vs. a sulfonylurea [42]\nAggressive therapy may not be the key to survival for localized prostate cancer\nOne-Minute Telegram 72-2023-3/3\n10-second takeaway\nAggressive therapy for prostate cancer (i.e., prostatectomy and/or radiotherapy) can reduce local disease progression and metastasis, but may lead to unnecessary procedures and serious side effects without improving long-term survival. In this long-term randomized clinical trial, fifteen-year mortality from prostate cancer was low and unaffected by the choice of initial treatment. Active monitoring may be an acceptable management option for patients with localized prostate cancer who wish to avoid the harms associated with aggressive therapy.\nStudy breakdown\n- Study population\n- Methods: long-term, randomized clinical trial\n- Randomization: 1:1:1 to standard treatment protocols for active monitoring, prostatectomy, or radiotherapy\n- Monitoring: scheduled monitoring of\n[PSA]+ management review and intervention triggered by increase in [PSA]\u2265 2 ng/dL or clinical concern\n- Primary outcome: death from prostate cancer\n- Secondary outcomes: all-cause mortality, metastases, clinical progression, and initiation of long-term\n[androgen](/de/wissen/Sexualhormone#Z30990f86bf408f16b9e5b25eaa0a1065)-deprivation therapy\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)follow-up: 15 years\n- Main results\n- No significant difference in prostate cancer mortality (prostate cancer specific survival was approximately 97% in all groups; P = 0.53)\n- No significant difference in all-cause mortality among trial groups\n- Metastasis was more common with active monitoring (9.4%) than prostatectomy (4.7%) or radiotherapy (5.0%).\n- Local disease progression was more common with active monitoring (25.9%) than prostatectomy (10.5%) or radiotherapy (11%).\n-\n[Androgen](/de/wissen/Sexualhormone#Z30990f86bf408f16b9e5b25eaa0a1065)deprivation therapy was more common with active monitoring (12.7%) than prostatectomy (7.2%) or radiotherapy (7.7%).\n- Proportion of patients who had received aggressive therapy by the end of 15 years of follow-up:\n- 61.1% in the active monitoring group\n- 90.4% in the prostatectomy group\n- 92.5% in the radiotherapy group\n- Limitations include: Diagnostic and treatment options have evolved since initiation of the trial.\n- Study funding: National Institute for Health and Care Research in the United Kingdom\n- Related AMBOSS article:\n[Prostatakarzinom](/de/wissen/Prostatakarzinom#Z8177a7d89a41809da02205b21a7b3283)\n- Original study: Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. [43]\nQ1 2023\n-\n[One-Minute Telegram 71-2023](/de/wissen/One-Minute_Telegram_Archiv#Zd4f88ef0ae8120cfba5d26c551223bb4)\n-\n[One-Minute Telegram 70-2023](/de/wissen/One-Minute_Telegram_Archiv#Z3bc56eab38bd731fd8976865e9039c20)\n-\n[One-Minute Telegram 69-2023](/de/wissen/One-Minute_Telegram_Archiv#Z2cc6695f2c802cebbaa177964b1c9a4e)\n-\n[One-Minute Telegram 68-2023](/de/wissen/One-Minute_Telegram_Archiv#Z3bcdbf81f579eff597aff89f336e7dd5)\n- After orthopedic trauma, two\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)a day keep fatal blood clots away\n- Loop me in: torsemide or\n[furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8)for heart failure?\n- They tested their poo, but didn\u2019t follow through\n- After orthopedic trauma, two\n-\n[One-Minute Telegram 67-2023](/de/wissen/One-Minute_Telegram_Archiv#Zf30f386211b8b086a1e9fc2354cb1eb4)\n-\n[Freezing](/de/wissen/Neurologische_Untersuchung#Z287079ef7739f4e5dc8bbdef88adaea4)the progression of atrial [fibrillation]\n-\n[Empagliflozin](/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398)improves outcomes in [chronic kidney disease](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)\n- Fluvoxamine: no panacea for\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\n-\n-\n[One-Minute Telegram 66-2023](/de/wissen/One-Minute_Telegram_Archiv#Z0e7fa357b14a93221ec72113b8aee537)\n- 2021 AHA/\n[ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32)model overestimates the risk of coronary artery disease\n- Chlorthalidone and\n[hydrochlorothiazide](/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8): not so different after all\n- I would walk 5000 steps, but should I walk 5000 more?\n- 2021 AHA/\nEdition 71 - March 25, 2023\nTRUNCATE-TB: Sometimes less isn\u2019t less\nOne-Minute Telegram 71-2023-1/3\n10-second takeaway\nThe currently recommended treatment regimen for drug-susceptible pulmonary tuberculosis (TB) may lead to overtreatment, nonadherance, and increased drug\n[resistance](/de/wissen/Lungenfunktionsuntersuchung#Z80d949a4d2a4efc1d0698d7d68ac9d2b). In this open-label trial with [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)-negative patients, a two-month bedaquiline- [linezolid](/de/wissen/Antibiotika_-_\u00dcbersicht#Zc2b39f2fb480726a0e60f8f676834a72) treatment regimen followed by extended treatment only for persistent or relapsing TB was noninferior to a standard six-month regimen with respect to death, persistent disease, and prolonged treatment. Shorter treatment regimens combined with extended monitoring may prevent overtreatment and reduce the cost of care.\nStudy breakdown\n- Study population: 674\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)-negative adults aged 18\u201365 years with symptoms or radiographic evidence of TB and a positive nucleic [acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f)test for TB without rifampin [resistance](/de/wissen/Lungenfunktionsuntersuchung#Z80d949a4d2a4efc1d0698d7d68ac9d2b)\n- Methods\n- International, randomized, phase 2\u20133 prospective, open-label noninferiority trial\n- Randomization to either of the following:\n- Standard therapy: 8 weeks of\n[isoniazid](/de/wissen/Tuberkulose#Z0a185ef468711f3a4465556d1e8632ec)(H) + rifampin (R) + pyrazinamide (Z) + [ethambutol](/de/wissen/Tuberkulose#Z8800fb076b10b48b18eb61516d6cddd7)(E) followed by 16 weeks of H + R\n- Shortened therapy: 8-week treatment with one of four different drug combinations followed by monitoring, extended treatment for persistent disease, and/or treatment for relapse\n- Standard therapy: 8 weeks of\n- Regular monitoring with symptom assessment and\n[sputum](/de/wissen/Pneumonie#Zebe53f3ed128a0207d97b438c04b867b)smears\n- Primary outcomes: composite of death, ongoing treatment, or active tuberculosis\n- Follow-up: at 96 weeks\n- Main results\n- Initial treatment with 8 weeks of H + Z + E + bedaquiline-\n[linezolid](/de/wissen/Antibiotika_-_\u00dcbersicht#Zc2b39f2fb480726a0e60f8f676834a72)was noninferior to standard therapy (adjusted difference, 0.8 percentage points; 97.5% CI, -3.4 to 5.1).\n- Initial treatment with 8 weeks of H + Z + E +\n[linezolid](/de/wissen/Antibiotika_-_\u00dcbersicht#Zc2b39f2fb480726a0e60f8f676834a72)+ high-dose R did not meet noninferiority criteria.\n-\n[Recruitment](/de/wissen/Audiometrische_Verfahren_in_der_HNO#Z7557366df45a5d8254c0fba4a82c9b27)to the remaining two therapy groups was discontinued due to sample size considerations.\n- No difference in\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c), death, or acquired drug [resistance](/de/wissen/Lungenfunktionsuntersuchung#Z80d949a4d2a4efc1d0698d7d68ac9d2b)between groups\n- Initial treatment with 8 weeks of H + Z + E + bedaquiline-\n- Limitations include:\n- Open-label design\n- Exclusion of\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)-positive participants\n- Study funding: Singapore National Medical Research Council and others\n- Original study: Treatment strategy for rifampin-susceptible tuberculosis [44]\n- AMBOSS links:\n[Tuberkulose](/de/wissen/Tuberkulose#Z0db057dcc7fab732110ea50e1288c24c)\n[Statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25) your case: high-intensity therapy vs. treat-to-target for elevated [LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163)-C\nOne-Minute Telegram 71-2023-2/3\n10-second takeaway\nStatins reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD), but the best strategy for initiating\n[statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25) therapy remains unclear. In this trial, moderate-intensity [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25) therapy followed by [titration](/de/wissen/S\u00e4ure-Basen-Haushalt#Za80458cfefac4891bb0c8bbff3987b11) to a targeted [LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163)-C level was noninferior to high-intensity [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25) therapy without a targeted [LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163)-C in reducing the risk for a composite of major cardiovascular events. In patients with CAD, [titration](/de/wissen/S\u00e4ure-Basen-Haushalt#Za80458cfefac4891bb0c8bbff3987b11) of moderate-intensity [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25) therapy to a target [LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163)-C goal may be as effective and safe as initiation of treatment with a high-intensity [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25).\nStudy breakdown\n- Study population: 4400 adults with clinically diagnosed CAD (mean age 65 years; 72% male)\n- Methods\n- Multicenter, open-label, randomized, noninferiority trial\n- Randomization of\n[statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)therapy 1:1 to:\n- High-intensity:\n[rosuvastatin](/de/wissen/Lipidsenker#Z1e78ee2e8336d5ff15ddeae7ef13d569)20 mg or [atorvastatin](/de/wissen/Lipidsenker#Zc0c8744cee387048609bafe6c953e2dd)40 mg once daily, no target [LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163)-C\n- Titrated-intensity:\n[rosuvastatin](/de/wissen/Lipidsenker#Z1e78ee2e8336d5ff15ddeae7ef13d569)10 mg or [atorvastatin](/de/wissen/Lipidsenker#Zc0c8744cee387048609bafe6c953e2dd)20 mg once daily followed by upward or downward [titration](/de/wissen/S\u00e4ure-Basen-Haushalt#Za80458cfefac4891bb0c8bbff3987b11)to target goal [LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163)-C of 50\u201370 mg/dL\n- High-intensity:\n- Primary endpoint: composite of all-cause death, myocardial infarction, stroke, or coronary revascularization\n- Follow-up: 3 years\n- Main results\n- Titrated-intensity\n[statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)therapy was noninferior to high-intensity [statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)therapy.\n- Primary endpoint: titrated-intensity group 8.1% vs. high-intensity group 8.7% (absolute difference, -0.6 percentage points [upper boundary of the 1-sided 97.5% CI, 1.1 percentage points])\n- All-cause death (absolute difference, < 0.1% [95% CI, -0.9% to 0.9%])\n- Myocardial infarction (absolute difference, -0.5% [95% CI, -1.1% to 0.1%])\n- Stroke (absolute difference, -0.5% [95% CI, -1.1% to 0.1%])\n- Titrated-intensity\n- Limitations include:\n- Open-label design\n- Study may have been underpowered, given lower-than-anticipated event rates.\n- The study did not consider the use of statins for primary prevention.\n- The study does not provide evidence on whether treatment-to-target results in improved outcomes, reduced adverse effects, and/or a better cost-benefit ratio compared with high-dose\n[statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)therapy.\n- Study funding: Samjin Pharmaceutical and Chong Kun Dang Pharmaceutical\n- Original study: Treat-to-target or high-intensity\n[statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)in patients with coronary artery disease: a randomized clinical trial [45]\n- AMBOSS links:\n[Atherosklerose](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z139361cb7eef098487c30705ba4a7975)| [Koronare Herzkrankheit](/de/wissen/Koronare_Herzkrankheit#Zfbf6e89e4c99b090c46d60c93fdd8ff1)| [Dyslipid\u00e4mien](/de/wissen/Dyslipid\u00e4mien#Z6f17254a240deb056c9f82d3fa69fac5)\nNOSTONE left unturned\nOne-Minute Telegram 71-2023-3/3\n10-second takeaway\n[Thiazide](/de/wissen/Thiaziddiuretika#Z326ee0b85f1a9567b91f36bfd180cda2) diuretics are commonly used to prevent the recurrence of [nephrolithiasis](/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c), but studies supporting this practice are limited. In this trial with patients in Switzerland with a history of recurrent [nephrolithiasis](/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c), daily [hydrochlorothiazide](/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8) (HCTZ) did not reduce the incidence of [nephrolithiasis](/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c) recurrence compared to [placebo] but did cause more hypokalemia, gout, and [plasma] creatinine elevation. The risks of daily [thiazide](/de/wissen/Thiaziddiuretika#Z326ee0b85f1a9567b91f36bfd180cda2) diuretic use should be weighed against the potential lack of benefit for prevention of recurrent [nephrolithiasis](/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c).\nStudy breakdown\n- Study population: 416 adults with a history of recurrent\n[calcium](/de/wissen/Wasser-_und_Elektrolythaushalt#Zca6be39e404895ed291688b168784eca)-containing kidney stones within 10 years ( [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age 49 years; 20% female; 99% White)\n- Methods\n- Main results\n- Stone recurrence was 59% in the\n[placebo]group and did not differ significantly compared to [placebo]in the HCTZ treatment groups:\n- 12.5 mg HCTZ group: 59% (rate ratio 1.33; 95% CI, 0.92\u20131.93)\n- 25 mg HCTZ group: 56% (rate ratio, 1.24; 95% CI, 0.86\u20131.79)\n- 50 mg HCTZ group: 49% (rate ratio, 0.92; 95% CI, 0.63\u20131.36)\n- Hypokalemia, gout, new-onset\n[diabetes mellitus](/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261), skin allergy, and [plasma]creatinine elevation > 150% [baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293)were more common in participants taking HCTZ than those taking [placebo].\n- Nonadherance rate was 26%.\n- Stone recurrence was 59% in the\n- Limitations include:\n- Underrepresentation of women and people of color\n- Results are not generalizable to the prevention of recurrence after a first episode of\n[nephrolithiasis](/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c).\n- Study duration of 3 years limits generalizability to longer treatment periods.\n- High incidence of nonadherance may have introduced\n[bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0)toward the null hypothesis.\n- Study funding: Swiss National Science Foundation; Inselspital, Bern University Hospital\n- Original study:\n[Hydrochlorothiazide](/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8)and prevention of kidney stone recurrence [46]\n- AMBOSS links:\n[Nephrolithiasis](/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c)\nEdition 70 - March 11, 2023\nThe\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f) of the [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06) vaccine is nothing to sneeze at\nOne-Minute Telegram 70-2023-1/3\n10-second takeaway\nRespiratory syncytial\n[virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870) ( [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06)) is an important cause of death and disease in older adults, accounting for over 12,000 deaths per year among this population in the US alone. In this large-scale, [placebo]-controlled phase 3 trial, a single dose of [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06) vaccine had an acceptable safety profile and significantly reduced the incidence of [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06) infection and [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06)-related lower respiratory tract disease in older adults. This [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06) vaccine may be a safe and effective method for protecting this population from both mild and severe manifestations of [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06) infection.\nStudy breakdown\n- Study population: 24,966 adults, \u2265 60 years of age (mean age 69.5 years; 52% female; 39% with comorbidities)\n- Methods\n- Ongoing international, randomized, phase 3 trial\n- Randomized 1:1 to receive a single dose of the RSVPreF3 OA vaccine vs.\n[placebo]for one [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06)season\n- Primary outcome: vaccine\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)against [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06)-related lower respiratory tract disease\n- Subgroup safety assessment, utilizing solicited and unsolicited reporting of injection site and systemic reactions\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)follow-up: 6.7 months\n- Main results\n- Vaccine\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)compared with [placebo]\n- 82.6% (96.95% CI, 57.9\u201394.1) for prevention of\n[RT-PCR]-confirmed [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06)-related lower respiratory tract disease (primary outcome)\n- 94.1% (95% CI, 62.4\u201399.9) for prevention of severe\n[RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06)-related lower respiratory tract disease\n- 71.7% (95% CI, 56.2\u201382.3) for prevention of\n[RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06)-related acute respiratory infection\n- Similar\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)for [RSV](/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06)A and B subtypes\n- 82.6% (96.95% CI, 57.9\u201394.1) for prevention of\n-\n[Adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)associated with the vaccine were transient and of mild to moderate severity.\n- Vaccine\n- Limitations include: small number of participants > 80 years of age\n- Study funding: GlaxoSmithKline\n[Biologicals](/de/wissen/Immunsuppressiva#Zc4f8bb61c1be8bf782272d0e9b088995)\n- Original study: Respiratory syncytial\n[virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870)prefusion F [protein](/de/wissen/Aminos\u00e4uren_und_Proteine#Z6760651e0606c30942f14701885fce12)vaccine in older adults [47]\n- AMBOSS links:\n[Geriatrie](/de/wissen/\u00dcbersicht_Geriatrie#Zd974d45f1bd7586d4a4b49bc962e9adc)| [Akute Bronchitis](/de/wissen/Akute_Bronchitis#Zeee17e2aa0c0e653e43bea1bf81c386b)\nUSPSTF reaffirms: Do not screen asymptomatic patients for HSV!\nOne-Minute Telegram 70-2023-2/3\n10-second takeaway\nSerologic testing for\n[herpes simplex](/de/wissen/Herpesvirus-Infektionen#Z919b941a8193eedb0ce87b453ae9885e) [virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870) (HSV) in patients without symptoms of genital herpes has a high false-positive rate, and whether treatment for asymptomatic HSV is warranted is controversial. The United States Preventive Services Task Force (USPSTF) has reaffirmed its recommendation against routine serologic screening for genital HSV in immunocompetent, [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)-negative, asymptomatic adolescents and adults, including pregnant individuals. Medical providers should avoid routine serologic screening for HSV in this population.\nRecommendation breakdown\n- Recommendation: The USPSTF recommends against routine serologic screening for genital HSV infection in asymptomatic adolescents and adults, including pregnant individuals.\n- Applicable population: adolescents and adults, including pregnant individuals, without a known medical history, signs, and/or symptoms of genital herpes\n- Additional information\n- Routine serologic screening for HSV has a low predictive value and a high rate of false positives in asymptomatic patients.\n- The benefit of antiviral medications in asymptomatic patients with serologic evidence of HSV infection is unclear.\n- This recommendation does not apply to:\n- Individuals with\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)or other immunosuppressive disorders\n- Individuals requesting testing who have signs, symptoms, or a history of genital herpes\n- Individuals with\n- Limitations include:\n- Need for more studies to assess the benefits and risks of screening for and management of genital herpes in asymptomatic individuals\n- Need for more studies to evaluate the potential benefits and risks of HSV screening in populations disproportionately affected by HSV\n- Study funding: Agency for Healthcare Research and Quality (AHRQ)\n- Original study: Serologic screening for genital herpes infection: US Preventive Services Task Force reaffirmation recommendation statement [48]\n- AMBOSS links:\n[Herpesvirus-Infektionen](/de/wissen/Herpesvirus-Infektionen#Z919b941a8193eedb0ce87b453ae9885e)| [Sexuell \u00fcbertragbare Infektionen](/de/wissen/Sexuell_\u00fcbertragbare_Infektionen#Zf2a474fc86c5ef68694e80ca13cd405b)\nSleep tight and keep your heart right\nOne-Minute Telegram 70-2023-3/3\n10-second takeaway\nThere is a clear correlation between disordered sleep and the development of cardiovascular disease (CVD). In this cross-sectional, community-based evaluation, irregularities in sleep duration and sleep onset timing were associated with subclinical atherosclerosis. Maintaining a regular sleep schedule with consistent sleep duration may be an important lifestyle recommendation for the prevention of CVD.\nStudy breakdown\n- Study population: 2032 US adults between 45 and 84 years of age (mean age 68 years; 53% female; 38% White; 28% Black; 23% Hispanic; 11% Chinese American)\n- Methods\n- Cross-sectional evaluation of participants in a longitudinal cohort study of atherosclerosis across six US communities\n- Sleep regularity was assessed with wrist-worn actigraphs and sleep diaries.\n- Standard deviations (SD) of sleep duration and sleep onset timing were determined for each participant.\n- The presence of subclinical CVD was determined using standard testing for:\n- Main results\n- Participants with irregular sleep duration (SD > 120 minutes) had a significantly higher likelihood of elevated CAC (prevalence ratio, 1.33; 95% CI, 1.03\u20131.71) and abnormal\n[ABI](/de/wissen/Periphere_arterielle_Verschlusskrankheit#Z1e2af43306a42a2270c69be33f51a20b)(1.75; 1.03\u20132.95) than those with regular sleep duration (SD \u2264 60 minutes).\n- Participants with irregular sleep onset timing (SD > 90 minutes) had higher CAC levels (1.39; 1.07\u20131.82) than those with regular sleep timing (SD \u2264 30 minutes).\n- Participants with irregular sleep duration (SD > 120 minutes) had a significantly higher likelihood of elevated CAC (prevalence ratio, 1.33; 95% CI, 1.03\u20131.71) and abnormal\n- Limitations include: Causality cannot be inferred given the cross-sectional study design.\n- Study funding\n- National Heart, Lung, and Blood Institute\n- National Center for Advancing Translational Sciences\n- Original study: Sleep irregularity and subclinical markers of cardiovascular disease: the multi-ethnic study of atherosclerosis [49]\n- AMBOSS links:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)| [Insomnie](/de/wissen/Insomnien#Z5e4895500dbde306d029b711e2ea238b)\nEdition 69 - February 25, 2023\nThe jury is still out on the best treatment approach to early\n[sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)\nOne-Minute Telegram 69-2023-1/3\n10-second takeaway\nThe best approach to\n[sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38) management is an area of active inquiry. This randomized trial of a restrictive vs. liberal fluid strategy for early management of [sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)-induced hypotension showed no difference in in-hospital mortality between the two groups. Whether these findings will affect current [sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38) management guidelines remains to be seen.\nStudy breakdown\n- Study population: 1563 adults < 4 hours after initial diagnosis of\n[sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)-induced hypotension refractory to initial resuscitation (1000\u20133000 mL of IV crystalloid fluid)\n- Methods: multicenter, randomized, nonblinded superiority trial\n- Randomized 1:1 to restrictive fluid strategy (prioritizing early\n[vasopressor]use with rescue fluids permitted) vs. liberal fluid strategy (prioritizing early fluid boluses with rescue [vasopressors]permitted) for 24 hours\n- Primary outcome: all-cause mortality prior to discharge by day 90\n- Randomized 1:1 to restrictive fluid strategy (prioritizing early\n- Main results\n- Patients in the restrictive fluid strategy group received an average of 2100 mL less IV fluid (3300 mL vs. 5400 mL) and were significantly more likely to receive\n[vasopressors]than the liberal fluid strategy group (59% vs. 37%).\n- No significant difference in mortality before discharge by day 90: 14.0% in the restrictive fluid strategy group; 14.9% in the liberal fluid strategy group (est. mean difference, -0.9%; 95% CI, -4.4 to 2.6)\n- No significant differences in invasive mechanical\n[ventilation](/de/wissen/Atemwege_und_Lunge#Zbffa82a865686699ed8a6fc3276b5293), onset of [ARDS](/de/wissen/Acute_Respiratory_Distress_Syndrome#Z154aa7c6d0bde152f7ea366b2d6834d0)within the first week of treatment, initiation of [renal](/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f)replacement therapy, or severe [adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)\n- Patients in the restrictive fluid strategy group received an average of 2100 mL less IV fluid (3300 mL vs. 5400 mL) and were significantly more likely to receive\n- Limitations include:\n- Results may not be generalizable to patients with volume overload or volume depletion on presentation, who were excluded from the study population, or to patients who develop\n[sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)in the hospital, since most participants were enrolled in the emergency department.\n- Trial may not have been powered to detect differences in outcomes among patient subgroups (e.g., patients with CHF and/or kidney disease)\n- Results may not be generalizable to patients with volume overload or volume depletion on presentation, who were excluded from the study population, or to patients who develop\n- AMBOSS links:\n[Sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)| [Fl\u00fcssigkeits- und Volumentherapie](/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z87e9a247724c9b2410076167606f4c20)\n- Original study: Early restrictive or liberal fluid management for\n[sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)-induced hypotension [50]\n- Authors: The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network\n- Journal: N Engl J Med\n- Study funding: NHLBI of the National Institutes of Health\nShed those meds: decreasing polypharmacy by actively deprescribing\nOne-Minute Telegram 69-2023-2/3\n10-second takeaway\nPolypharmacy, with its associated costs and adverse effects, is a growing concern among older adults that is often exacerbated by additional prescriptions upon hospital discharge. In this randomized clinical trial, hospitalized patients assigned to a deprescription intervention upon discharge to a post acute care (PAC) facility were prescribed significantly fewer medications at PAC facility discharge and at 90-day follow-up than patients receiving usual care. To reduce polypharmacy in older adults, hospital providers should consider introducing deprescription interventions before discharge.\nStudy breakdown\n- Study population: 372 adults over 50 years of age (mean age 76 years, 62% women) taking at least five prehospital medications (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)number 16) and being discharged from the hospital to a PAC facility\n- Methods: randomized clinical trial\n- Randomized 1:1 to receive the \u201cShed-MEDS intervention\u201d (comprehensive medication review\n[prompting](/de/wissen/Psychotherapeutische_Verfahren_(Klinik)#Z287bafc91b62572585c8c77c0a431a84)deprescribing recommendations implemented with patient approval and continued throughout PAC facility stay) vs. usual care\n- Follow-up at PAC facility discharge and 90 days post-PAC discharge\n- Randomized 1:1 to receive the \u201cShed-MEDS intervention\u201d (comprehensive medication review\n- Main results: Compared to usual care the intervention group had\n- 14% fewer medications at PAC facility discharge (mean ratio, 0.86; 95% CI, 0.80\u20130.93) and 15% fewer medications 90 days post-PAC discharge (0.85; 0.78\u20130.92)\n- Significantly lower medication dosages as measured by the Drug Burden Index\n- Reduced exposure to potentially inappropriate medications\n- Similar rates of adverse drug events\n- Limitations include:\n- Potentially limited generalizability, as patients were enrolled at a single academic medical center\n- By increasing\n[awareness]of polypharmacy, the study may have also led to avoidance of overprescribing for the nonintervention group, thus limiting the observed intervention effect.\n- AMBOSS link:\n[Geriatrie](/de/wissen/\u00dcbersicht_Geriatrie#Zd974d45f1bd7586d4a4b49bc962e9adc)\n- Original study: Deprescribing medications among older adults from end of hospitalization through postacute care: a Shed-MEDS randomized clinical trial [51]\n- Authors: Vasilevskis EE, Shah AS, Hollingsworth EK, et al.\n- Journal: JAMA Intern Med\n- Study funding: National Institute on Aging of the National Institutes of Health\nDoes\n[vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84) prevent diabetes in people with prediabetes?\nOne-Minute Telegram 69-2023-3/3\n10-second takeaway\nFactors associated with the prevention of type 2 diabetes in individuals at risk are an area of active research. In this systematic review and metaanalysis of three randomized trials, patients with prediabetes who received\n[oral] [vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84) therapy had a moderately reduced risk of developing diabetes compared to those who received [placebo]. [Oral] [vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84) therapy may be a safe and effective adjunct to other measures for the prevention of diabetes in patients with prediabetes.\nStudy breakdown\n- Study population: 4190 adults (mean age 61 years, 44% women, 51% White, 33% Asian, 15% Black) with prediabetes\n- Methods: systematic review and individual participant data metaanalysis from three randomized clinical trials\n- Randomized 1:1 to receive\n[oral] [vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)( [cholecalciferol](/de/wissen/Vitamine#Z3cebeed83653053fef153c67a295db41)20,000 IU weekly, [cholecalciferol](/de/wissen/Vitamine#Z3cebeed83653053fef153c67a295db41)4000 IU daily, or eldecalcitol 0.75 mcg daily) vs. [placebo]\n- Primary outcome: time to onset of diabetes\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)follow-up: 3 years\n- Randomized 1:1 to receive\n- Main results: Compared to patients receiving\n[placebo], patients in the [vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)group had\n- Lower rates of developing diabetes (22.7% vs. 25%; adjusted HR, 0.85; 95% CI, 0.75\u20130.96)\n- Higher rates of normalization of\n[glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57)regulation (14.4% vs. 11.1%; rate ratio, 1.30; 1.16\u20131.46)\n- Similar rates of\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)(kidney stones, hypercalcemia, hypercalciuria) and death\n- Limitations include:\n- Results are not generalizable to populations without prediabetes or other dosages of\n[vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)replacement.\n- Results are not generalizable to populations without prediabetes or other dosages of\n- AMBOSS links:\n[Diabetes mellitus](/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261)\n- Original study:\n[Vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)and risk for type 2 diabetes in people with prediabetes [52]\n- Authors: Pittas AG, Kawahara T, Jorde R, et al.\n- Journal: Ann Intern Med\n- Study funding: None\nEdition 68 - February 11, 2023\nAfter orthopedic trauma, two\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) a day keep fatal blood clots away\nOne-Minute Telegram 68-2023-1/3\n- Background:\n[Low molecular weight heparin](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a)( [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a)) is recommended for thromboprophylaxis in patients with fractures. This trial set out to determine if [aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)is noninferior to [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a)as thromboprophylaxis after a fracture.\n- Study population: 12,211 adults (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age 44 years, 62% male) with any pelvic, [acetabular](/de/wissen/Becken_und_H\u00fcfte#Z0258fe63773be508fb74c6409eb1e1f9), and/or surgically repaired extremity fracture\n- Methods\n- Main results\n- Mortality was similar between\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)(0.78%) and [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a)(0.73%) groups (96.2% CI, -0.27 to 0.38).\n- Incidence of pulmonary embolism was the same in both groups (1.49%).\n- Deep vein thrombosis occurred more frequently in the\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)group than in the [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a)group (2.51% vs. 1.71%; 95% CI, 0.28\u20131.31).\n- Safety outcomes: Incidence of bleeding complications and other serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)was similar between groups.\n- Mortality was similar between\n- Limitations include:\n- Open-label design may have introduced surveillance\n[bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0).\n- Variations in the duration of thromboprophylaxis may have influenced outcomes.\n- Generalizability to other patient groups is limited.\n- Open-label design may have introduced surveillance\nThe take-home message?\nIn this large, open-label trial,\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) was noninferior to [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a) as thromboprophylaxis after a fracture. [Aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) may be a well-tolerated, effective, inexpensive, and convenient alternative to [LMWH](/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a) following orthopedic trauma.\n- AMBOSS links:\n[Tiefe Beinvenenthrombose](/de/wissen/Phlebothrombose#Z28ca7507422e8791c7b034c316a126e1)| [Lungenarterienembolie](/de/wissen/Lungenembolie#Z109ebdc29405d0f0b7670dc604254fcd)\n- Original study:\n[Aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)or low-molecular-weight [heparin](/de/wissen/Nicht-orale_Antikoagulation#Zad69ea8aed3a6bbd4fda7fc9c0572707)for thromboprophylaxis after a fracture [53]\n- Authors: Major Extremity Trauma Research Consortium\n- Journal: N Engl J Med\n- Study funding: Patient-Centered Outcomes Research Institute\nLoop me in: torsemide or\n[furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8) for heart failure?\nOne-Minute Telegram 68-2023-2/3\n- Background: Loop diuretics are a cornerstone in the management of heart failure, and torsemide may be more effective than other diuretics because of its high bioavailability and long half-life. This study set out to determine if torsemide is more effective than\n[furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8)for reducing mortality in patients hospitalized for acute heart failure.\n- Study population: 2859 patients (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age 65 years, 36.9% female) hospitalized for de novo heart failure or worsened chronic heart failure\n- Methods\n- Open-label, pragmatic, randomized comparative-effectiveness study\n- Randomized 1:1 to torsemide or\n[furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8)on discharge\n- Dosage was clinician-determined (recommended drug equivalency was 1 mg torsemide to 2\u20134 mg\n[furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8)).\n-\n[Recruitment](/de/wissen/Audiometrische_Verfahren_in_der_HNO#Z7557366df45a5d8254c0fba4a82c9b27)ended upon reaching a predetermined number of all-cause deaths ( [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)follow-up was 17.4 months).\n- Main results\n- No difference in all-cause mortality: 26.1% in the torsemide group, 26.2% in the\n[furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8)group (HR, 1.02; 95% CI, 0.89\u20131.18)\n- No difference in total hospitalizations: 940 in the torsemide group, 987 in the\n[furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8)group (RR, 0.94; 0.84\u20131.07)\n- Mean\n[furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8)equivalent diuretic doses were similar at discharge in both groups: 79.1 mg in the [furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8)group, 79.5 mg in the torsemide group\n- Crossover occurred in 5.4%; nonadherence at 6 months was 9.5%.\n- No difference in all-cause mortality: 26.1% in the torsemide group, 26.2% in the\n- Limitations include:\n- Early attainment of the predetermined study endpoint resulted in a smaller-than-anticipated sample size, which limited subgroup analyses and assessments of subtle benefits and harms.\n- All-cause mortality may have been too broad an outcome to detect subtle differences between drugs.\n- High crossover and nonadherence rates may have introduced\n[bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0)toward neutral results.\nThe take-home message?\nIn this large open-label randomized clinical trial, the use of torsemide vs.\n[furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8) following hospitalization for heart failure did not result in a significant difference in all-cause mortality at 12 months. These results suggest that the pharmacokinetic advantages of torsemide may not be clinically significant, but study limitations necessitate cautious interpretation.\n- AMBOSS links:\n[Dekompensierte Herzinsuffizienz](/de/wissen/Herzinsuffizienz#Z159958c8b33e83f2f05f57847f5139ff)\n- Original study: Effect of torsemide vs\n[furosemide](/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8)after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM- [HF](/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4)randomized clinical trial [54]\n- Authors: Mentz RJ, Anstrom\n[KJ], Eisenstein EL et al.\n- Journal: JAMA\n- Study funding: National Institutes of Health\nThey tested their poo, but didn\u2019t follow through\nOne-Minute Telegram 68-2023-3/3\n- Background: Colonoscopy is recommended after a positive stool-based test (SBT) for colorectal cancer (\n[CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)) screening. This study investigated the rates of and factors associated with follow-up colonoscopy (FU-CY) after a positive SBT.\n- Study population: 32,769 primary care patients aged 50\u201370 years with an average risk of\n[CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)and a positive SBT\n- Methods: retrospective analysis of anonymized electronic health records\n- Main results\n- FU-CY was performed within 360 days of a positive SBT in 56.1% of patients.\n- White patients were more likely to have FU-CY than Black patients (HR, 0.85; 95% CI, 0.80\u20130.91) or Asian patients (0.79; 0.69\u20130.91).\n- Individuals with commercial insurance were more likely to have FU-CY than those with Medicare (0.95; 0.91\u20130.99) or Medicaid (0.79; 0.73\u20130.85).\n- Patients tested with multitarget stool\n[DNA](/de/wissen/Aufbau_von_DNA_und_RNA#Zc937104d20e3073b9c1a31fba7065b8d)tests were more likely to have FU-CY than those who had a fecal immunochemical test (1.63; 1.57\u20131.68).\n- FU-CY rates were lower in 2020 than in 2019, which the authors attribute to the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)pandemic.\n- Limitations include:\n- Analysis of electronic health records data may have led to\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1).\n- Generalizability to other populations is limited.\n- Analysis of electronic health records data may have led to\nThe take-home message?\nIn this large retrospective study, FU-CY occurred less frequently than recommended, especially among Black and Asian patients, those with noncommercial insurance, and those who had a fecal immunochemical test. Physicians screening for\n[CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7) should be aware of this potential gap in care to help prevent complications and mortality related to delayed diagnosis and treatment of [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7).\n- AMBOSS links:\n[Kolorektales Karzinom](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)| [Kolonpolypen](/de/wissen/Kolonpolypen#Z7d836a80066e57b74c74add53eea2731)\n- Original study: Rates of follow-up colonoscopy after a positive stool-based screening test result for colorectal cancer among health care organizations in the US, 2017-2020 [55]\n- Authors: Mohl JT, Ciemins EL, Miller-Wilson L et al.\n- Journal: JAMA Netw Open\n- Study funding: Exact Sciences Corporation\nEdition 67 - January 28, 2023\n[Freezing](/de/wissen/Neurologische_Untersuchung#Z287079ef7739f4e5dc8bbdef88adaea4) the progression of atrial [fibrillation]\nOne-Minute Telegram 67-2023-1/3\n- Background:\n[Paroxysmal]atrial [fibrillation](AF) frequently progresses to persistent AF, [56] which is associated with higher rates of thromboembolism, heart failure, and health care utilization. Early cryoablation therapy reduces the recurrence of atrial tachyarrhythmias within the first year of treatment compared to antiarrhythmic drug therapy. [57] This follow-up analysis set out to determine whether early cryoablation has longer-term disease-modifying benefits.\n- Study population: 303 patients with untreated\n[paroxysmal]AF\n- Methods: multicenter, open-label randomized trial\n- Rhythm control therapy with cryoballoon ablation (n = 154) or antiarrhythmic drug therapy (n = 149)\n- Cardiac events were recorded using implantable loop recorders.\n- Follow-up: 3 years\n- Main results (\n[intention-to-treat](/de/wissen/Studientypen_der_medizinischen_Forschung#Z12db0a61af1774ca03f632559492fe19)analysis)\n- Episodes of persistent AF (lasting > 7 days or lasting > 48 hours and requiring cardioversion)\n- Ablation group: 1.9%\n- Antiarrhythmic drug group: 7.4%\n- HR, 0.25; 95% CI, 0.09\u20130.70\n- Recurrent atrial tachyarrhythmia (lasting \u2265 30 seconds)\n- Ablation group: 56.5%\n- Antiarrhythmic drug group: 77.2%\n- HR, 0.51; 0.38\u20130.67\n- Hospitalization\n- Ablation group: 5.2%\n- Antiarrhythmic drug group: 16.8%\n- Relative risk, 0.31; 0.14\u20130.66\n- Trend toward lower risk of serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)in the ablation group (RR, 0.45; 0.19\u20131.05)\n- Episodes of persistent AF (lasting > 7 days or lasting > 48 hours and requiring cardioversion)\n- Limitations include:\n- 18 patients crossed over to the ablation group after unsuccessful medical therapy.\n- Outcomes may not be generalizable to other ablation techniques.\nThe take-home message?\nOver a 3-year follow-up, patients with\n[paroxysmal] AF treated with early cryoballoon ablation had lower rates of progression to persistent AF, recurrent atrial tachyarrhythmia, and hospitalization compared to patients treated with antiarrhythmic drug therapy. Larger trials are required to assess whether cryoballoon ablation can also reduce rates of stroke, heart failure, and death in this patient population.\n- AMBOSS links:\n[Vorhofflimmern](/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266)\n- Original study: Progression of atrial\n[fibrillation]after cryoablation or drug therapy [58]\n- Authors: Andrade JG et al.\n- Journal: NEJM\n- Study funding: Cardiac Arrhythmia Network of Canada and others\n[Empagliflozin](/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398) improves outcomes in [chronic kidney disease](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)\nOne-Minute Telegram 67-2023-2/3\n- Background:\n[SGLT2](/de/wissen/Tubul\u00e4re_Transportprozesse#Z147bc6f1ad1901fc8ed06311e1ce0e9f)inhibitors reduce the risk of [chronic kidney disease](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)( [CKD](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)) progression in patients with proteinuric [CKD](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)and type 2 diabetes. [59][60] This study set out to assess the effects of [empagliflozin](/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398)on a diverse group of patients with [CKD](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849), including those without diabetes or proteinuria.\n- Study population: 6609 adults with\n[CKD](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)(mean age 63.8 years; 33.2% women; 54% without diabetes) with an estimated glomerular filtration rate ( [eGFR]) of 20\u201345 mL/min/1.73 m2, regardless of albuminuria, or an [eGFR]of 45\u201390 mL/min/1.73 m2 and a urinary [albumin](/de/wissen/Laboratoriumsmedizin#Z17520cb42bfb4e42a2e7ab25d2d0dd78):creatinine ratio \u2265 200 mg/g\n- Methods: double-blind randomized controlled trial\n-\n[Empagliflozin](/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398)10 mg or [placebo]once daily\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)follow-up: 2 years\n-\n- Main results\n- Primary outcome: progression of\n[CKD](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)or death from cardiovascular causes\n-\n[Empagliflozin](/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398)group: 13.1%\n-\n[Placebo]group: 16.9%\n- HR, 0.72; 95% CI, 0.64\u20130.82\n- No significant differences across\n[eGFR]subgroups nor between patients with or without diabetes\n-\n- Secondary outcomes\n- Lower rate of hospitalization in the\n[empagliflozin](/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398)group (HR, 0.86; 0.78\u20130.95)\n- No difference in all-cause mortality or composite of heart failure hospitalizations and cardiovascular death\n- Lower rate of hospitalization in the\n- Similar rates of serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)between groups\n- Primary outcome: progression of\n- Limitations include: A low number of cardiovascular events may have reduced the statistical\n[power](/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e)for the assessment of secondary outcomes.\nThe take-home message?\nPatients with\n[CKD](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849) treated with [empagliflozin](/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398) had lower rates of [CKD](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849) progression or cardiovascular mortality than those who received [placebo], regardless of diabetes status or [eGFR] subgroup.\n- AMBOSS links:\n[Chronische Nierenerkrankung](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)| [SGLT2-Inhibitoren](/de/wissen/Antidiabetika#Z8cb9f0d09ce5db412af4be69feb68a26)\n- Original study:\n[Empagliflozin](/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398)in patients with [chronic kidney disease](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)[61]\n- Authors: The EMPA-KIDNEY Collaborative Group\n- Journal: N Engl J Med\n- Study funding: Boehringer Ingelheim and others\nFluvoxamine: no panacea for\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nOne-Minute Telegram 67-2023-3/3\n- Background: A recent metaanalysis suggests that fluvoxamine, a selective\n[serotonin](/de/wissen/Nervengewebe,_Synapsen_und_Transmitter#Zabfae2472ee779feb0ae2fba3c36e946)reuptake inhibitor with antiinflammatory effects, can reduce [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)-related hospitalizations. [62][63] However, high-quality randomized studies demonstrating a benefit with fluvoxamine for the treatment of [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)have so far been lacking.\n- Study population: 1288 patients \u2265 30 years of age (mean age 47 years; 57% female) with mild-to-moderate\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)with > 2 symptoms for < 7 days\n- Methods: randomized controlled adaptive platform trial [64]\n- Fluvoxamine (50 mg; n = 674) or\n[placebo](n = 614) twice daily for 10 days\n- Follow-up: 28 days\n- Fluvoxamine (50 mg; n = 674) or\n- Main results\n- Primary outcome:\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)time to recovery (3 consecutive symptom-free days)\n- Fluvoxamine group: 12 days (IQR, 11\u201314 days)\n-\n[Placebo]group: 13 days (IQR, 12\u201313 days)\n- HR, 0.96; 95% credible interval, 0.86\u20131.06\n- Secondary outcome: composite of hospitalization, urgent care or ED visit, or death\n- Fluvoxamine group: 3.8%\n-\n[Placebo]group: 3.9%\n- HR, 1.1; 0.5\u20131.8\n- Similar rates of\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)and duration of symptoms in both groups\n- Primary outcome:\n- Limitations include:\n- Study likely underpowered to detect a difference in secondary outcome because of the low number of clinical events in both groups\n- Significant delay from symptom onset to treatment initiation (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b): 5 days)\nThe take-home message?\nIn this\n[RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28), fluvoxamine did not improve clinical outcomes in patients with mild-to-moderate [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) compared to [placebo].\nEdition 66 - January 14, 2023\n2021 AHA/\n[ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32) model overestimates the risk of coronary artery disease\nOne-Minute Telegram 66-2023-1/3\n- Background: Pretest probability (\n[PTP]) models for obstructive coronary artery disease (CAD) include the European Society of Cardiology [PTP](ESC- [PTP]) model, risk factor-weighted clinical likelihood (RF-CL) model, and the 2021 American Heart Association/American College of Cardiology [PTP](AHA/ [ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32)- [PTP]) model. [66][67][68] The aim of this study was to determine whether [PTP]models that categorize chest pain (ESC- [PTP]and RF-CL) and/or include additional risk factors (RF-CL) are more accurate than the AHA/ [ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32)- [PTP].\n- Study population: 50,561 patients (mean age 57.3 years, 54% female) with symptoms suggestive of obstructive CAD, without previously diagnosed CAD, receiving first-time coronary computed tomography angiography (CCTA)\n- Methods: multicenter cohort study between 2008 and 2019\n- Main results\n- Obstructive CAD prevalence: 8.0%\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)predicted prevalence of obstructive CAD\n- RF-CL had the highest accuracy (P < 0.001)\n- AHA/\n[ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32)- [PTP]had lower accuracy in predicting prevalence of CAD than ESC- [PTP](P < 0.001).\n- AHA/\n[ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32)- [PTP]model overestimated the prevalence of CAD by a factor of 2.6 (2.6\u20132.7); overestimation was highest (factor of 4.8) in patients with nonanginal pain.\n- Limitations include:\n- Limited generalizability of results\n- Patients in the database used were predominantly White.\n- Patients with severe kidney disease and arrhythmias or severe obesity were not included.\n- Risk of\n[selection bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de): All participants had been referred for CTA, which excluded very low-risk patients.\n- Limited generalizability of results\nThe take-home message?\nThe AHA/\n[ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32)- [PTP] model significantly overestimated the prevalence of obstructive CAD. Models that include risk factors for CAD and symptom characteristics have the highest accuracy and may reduce unnecessary testing in patients with a low [PTP] of obstructive CAD. Care should be taken in generalizing these results to populations not included in this study.\n- AMBOSS links:\n[Akutes Koronarsyndrom](/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b)| [Koronare Herzkrankheit](/de/wissen/Koronare_Herzkrankheit#Zfbf6e89e4c99b090c46d60c93fdd8ff1)\n- Original study: Performance of the American Heart Association/American College of Cardiology guideline-recommended pretest probability model for the diagnosis of obstructive coronary artery disease [69]\n- Authors: Winther S et al.\n- Journal: JAHA\n- Study funding: Novo Nordisk Foundation\nChlorthalidone and\n[hydrochlorothiazide](/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8): not so different after all\nOne-Minute Telegram 66-2023-2/3:\n- Background: Chlorthalidone (CTD) is the preferred\n[thiazide](/de/wissen/Thiaziddiuretika#Z326ee0b85f1a9567b91f36bfd180cda2)diuretic antihypertensive according to the 2017 [ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32)/AHA hypertension guidelines, [70] but recent research has shown that [hydrochlorothiazide](/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8)(HCTZ) may have similar [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)to CTD in preventing cardiovascular disease (CVD) events, with a lower risk of [adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c). [71] This study compared the effect of CTD vs. HCTZ on the risk of major CVD events.\n- Study population: 13,523 adults in the Veterans Affairs Healthcare System \u2265 65 years of age receiving HCTZ for hypertension (mean age 72 years, 97% male, 15% Black)\n- Methods: multicenter, pragmatic, open-label trial (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)follow-up 2.4 years)\n- Patients were randomized to either remain on HCTZ (25 mg or 50 mg) or switch to\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f)D (12.5 mg or 25 mg).\n- Primary outcome: composite of non-cancer-related deaths and nonfatal CVD events, e.g., myocardial infarction (MI) or stroke\n- Secondary outcomes: individual components of primary outcome\n- Safety outcomes include electrolyte abnormalities, hospitalization, and\n[acute kidney injury](/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4).\n- Patients were randomized to either remain on HCTZ (25 mg or 50 mg) or switch to\n- Main results\n- No between-group differences in primary outcome (HR, 1.04; 95% CI, 0.94\u20131.16) or secondary outcomes\n- Hypokalemia: 6.0% in the\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f)D group, 4.4% in the HCTZ group (HR, 1.38; 1.19\u20131.60)\n- Subgroup analyses\n- Limitations include:\n- Open-label design may have influenced adherence and testing frequency.\n- Results may not be applicable to higher doses of\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f)D or HCTZ.\n- Generalizability: Study population was 97% male.\nThe take-home message?\nPatients with hypertension receiving HCTZ had a similar risk of CVD events and non-cancer-related death compared to patients receiving CTD at 2.4 years follow-up. Care should be taken in generalizing these results to higher medication doses and patients with a history of a major CVD event.\n- AMBOSS links:\n[Arterielle Hypertonie](/de/wissen/Arterielle_Hypertonie#Z3d73ccc1b405184a8d3087bd8b727eb4)| [Akutes Koronarsyndrom](/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b)| [Koronare Herzkrankheit](/de/wissen/Koronare_Herzkrankheit#Zfbf6e89e4c99b090c46d60c93fdd8ff1)\n- Original study: Chlorthalidone vs.\n[hydrochlorothiazide](/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8)for hypertension\u2013cardiovascular events [72]\n- Authors: Ishani A et al.\n- Journal: NEJM\n- Study funding: Veterans Affairs Cooperative Studies Program\nI would walk 5000 steps, but should I walk 5000 more?\nOne-Minute Telegram 66-2023-3/3:\n- Background: The oft-cited recommendation to take 10,000 steps/day originated as a marketing campaign, not from the scientific literature. The aim of this trial was to assess whether daily step count is associated with the risk of cardiovascular disease (CVD) events.\n- Study population: 20,152 adults \u2265 18 years of age (mean age 63 years, 52% female, > 70% non-Hispanic White)\n- Methods: metaanalysis of 8 prospective studies (mean follow-up 6.2 years)\n- Study requirements: device-measured steps and follow-up for CVD events\n- Step volume: average steps per day over a single 3\u20137-day period\n- Primary outcome: first subsequent CVD event (stroke, coronary artery disease, heart failure) stratified by sex and age\n- Main results\n- In participants \u2265 60 years of age, 6000\u20139000 steps/day was associated with an approx. 50% lower risk of CVD events compared to 2000 steps/day (HR, 0.51; 95% CI, 0.41\u20130.63).\n- In adults < 60 years of age, steps/day was not associated with risk of CVD events.\n- There were no subgroup differences in risk of CVD events by sex.\n- Limitations include:\n- Potential for residual\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1)and reverse causality\n- Follow-up period may not have been long enough to capture benefits of higher steps/day in young adults.\n- Potential for residual\nThe take-home message?\nHigher steps/day were associated with a lower risk of CVD events than lower steps/day in adults \u2265 60 years of age. Benefits also began with step counts well below the widely promoted 10,000 steps/day.\n- AMBOSS links:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)\n- Original study: Prospective association of daily steps with cardiovascular disease: a harmonized meta-analysis [73]\n- Authors: Paluch AE et al.\n- Journal: Circulation\n- Study funding:\n[Centers for Disease Control and Prevention]", "language": null, "image": "https://manus-media.amboss.com/pa-images/facebook-preview-1.jpg", "pagetype": "website", "links": ["https://www.amboss.com", "https://www.amboss.com/de/account/register?nextLink=%2Farticle%2FJF0sQ3", "https://www.amboss.com/de/account/login?nextLink=%2Farticle%2FJF0sQ3", "https://www.amboss.com/de/account/register", "https://www.amboss.com/de/disclaimer", "/de/wissen/Ohr#Z2e6489810ab8a5524d8534501fcab9be", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z589a0ddc97166bcc581756c355b29330", "/de/wissen/One-Minute_Telegram_Archiv_2021#Zedc2f5a9b0e39469c09137ff9a4dcb1e", "/de/wissen/One-Minute_Telegram_Archiv_2020#Ze765573a3b5d8aa28f098b044fb31e6e", "/de/wissen/One-Minute_Telegram_Archiv#Z7e824584e9377de6dad3721cd5af80ba", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/One-Minute_Telegram_Archiv#Zfffc9e0a62f07e67ff85803a8b5f30cf", "/de/wissen/Opioide#Z9d43413a5f7e7cb1d1b517ae170633bc", "/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z1b611565453ac185d256a499f1f3e862", "/de/wissen/Schock#Z9b54e135690b2b7579ca9e2b356f4974", "/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/\u00dcbersicht_des_Verdauungssystems#Zaa3f0692fb4127b17e934892e975ec10", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", null, "/de/wissen/Thrombozytenaggregationshemmer#Zf9a34ccbcc6b56f5ba55ee8f7136ac8d", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Transfusionen#Zd803a34f176dcce85995c063e76f09f1", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Gastrointestinale_Blutung#Zb253fc96ffb1591e2e428648851ad8c0", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", null, "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81", null, null, "/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4", "/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4", "/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Diabetes_mellitus#Z9b391484e159ca36f77f4655461c0450", "/de/wissen/Physiologische_Aspekte_pr\u00e4-_und_postnatal#Zfa6180c135c11222f20e4c1c738186b1", null, "/de/wissen/Hypertensive_Schwangerschaftserkrankungen#Zba4240f962fd7e4712a40becf9b43e84", "/de/wissen/Vorsorgeuntersuchungen_in_der_Schwangerschaft#Z2b7f8151a4f6a203e695b45aabb57fd8", "/de/wissen/Opioide#Z9d43413a5f7e7cb1d1b517ae170633bc", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z9d43413a5f7e7cb1d1b517ae170633bc", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z9d43413a5f7e7cb1d1b517ae170633bc", "/de/wissen/Opioide#Z9d43413a5f7e7cb1d1b517ae170633bc", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", null, "/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z2617c4a1c8650f5bf241213ea0311b58", "/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z76aa6b4f42cf89c1f5aca166ccf1f874", "/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3", "/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3", "/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4", "/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3", "/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4", null, "/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3", null, "/de/wissen/Herzinsuffizienz#Zf4df35c22cb16c63ac506d4eed4b8277", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", null, "/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3", null, "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4", null, "/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Herzinsuffizienz#Z0fcca00a61e903b8003b2bec6cf0b6a3", "/de/wissen/One-Minute_Telegram_Archiv#Z8eb8ab88ce8c9bcad538e75ef0f4f477", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/One-Minute_Telegram_Archiv#Z09756718c7d204b204e1cd78fe5e0c7a", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/Gewebshormone#Zd51752a55c3c4527e4b42765f0bc965a", "/de/wissen/One-Minute_Telegram_Archiv#Zb80a07416434b8291c7968e6acfd153a", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9", "/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874", "/de/wissen/One-Minute_Telegram_Archiv#Z463c8c90088c3f50831a5fc26e2465bc", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02", null, "/de/wissen/One-Minute_Telegram_Archiv#Ze776aa3e9343ef527988f9c7d3c5ba5f", "/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/One-Minute_Telegram_Archiv#Z52894ed8a09e8067dffaa93a5a611761", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/One-Minute_Telegram_Archiv#Z890df07b26e65528d01c5125af1e188c", "/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602", "/de/wissen/Nitrate_und_Molsidomin#Z297e68c91e1cac660e7d5df4acb11c80", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Phlebothrombose#Z28ca7507422e8791c7b034c316a126e1", "/de/wissen/Lungenembolie#Z109ebdc29405d0f0b7670dc604254fcd", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", null, "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Herzmechanik#Z3ec8a19368d15af640816443577a9cf5", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de", "/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e", "/de/wissen/Isch\u00e4mischer_Schlaganfall#Z132d7774d1cef997981d05c36a439551", "/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552", "/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552", "/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Myokardinfarkt#Za340e577f9ff67b72ee87080e1d8758b", "/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552", "/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Ze6b9e07de12b78c904d196ec3c9d772b", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Ze6b9e07de12b78c904d196ec3c9d772b", "/de/wissen/Immunsuppressiva#Z243798dbd864f1f85dfbc0f0feeaa79c", null, "/de/wissen/Herzkatheteruntersuchung#Z2bd538392880acb9f91148967c00d552", "/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Sexuell_\u00fcbertragbare_Infektionen#Zf2a474fc86c5ef68694e80ca13cd405b", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/Sexuell_\u00fcbertragbare_Infektionen#Zf2a474fc86c5ef68694e80ca13cd405b", "/de/wissen/Hepatitis_B_und_HBV-Infektion#Z0cc1ba9a62130e5544df273f6b9fb8aa", "/de/wissen/Lipide#Z8c94ec3e8e06e82aa0ca6a93b74d282d", "/de/wissen/Virostatika#Zf735d1aa1d436e2f0fe90a8a8c71d4af", null, "/de/wissen/HIV-Infektion#Z2df1d847fdbe4b665b60d68dc7e4f76f", null, "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/Sexuell_\u00fcbertragbare_Infektionen#Zf2a474fc86c5ef68694e80ca13cd405b", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Lungenfunktionsuntersuchung#Z80d949a4d2a4efc1d0698d7d68ac9d2b", "/de/wissen/Virostatika#Zf735d1aa1d436e2f0fe90a8a8c71d4af", "/de/wissen/HIV-Infektion#Z2df1d847fdbe4b665b60d68dc7e4f76f", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", null, "/de/wissen/Virostatika#Zf735d1aa1d436e2f0fe90a8a8c71d4af", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/HIV-Infektion#Z26c9be856bc6353677952780f5d4a5d2", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Z54541a53e014f60bb262be162cea06e7", "/de/wissen/Laboratoriumsmedizin#Zee26dc10887db5c92bedaa1d1cc3e6c1", "/de/wissen/Laboratoriumsmedizin#Zee26dc10887db5c92bedaa1d1cc3e6c1", "/de/wissen/Laboratoriumsmedizin#Zee26dc10887db5c92bedaa1d1cc3e6c1", "/de/wissen/Laboratoriumsmedizin#Zee26dc10887db5c92bedaa1d1cc3e6c1", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z91064578493b1b11a03044f853e7eec6", "/de/wissen/Gewebshormone#Zd51752a55c3c4527e4b42765f0bc965a", "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", "/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa", "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", "/de/wissen/Gewebshormone#Zd51752a55c3c4527e4b42765f0bc965a", "/de/wissen/Gewebshormone#Zd51752a55c3c4527e4b42765f0bc965a", "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", null, "/de/wissen/Gewebshormone#Zd51752a55c3c4527e4b42765f0bc965a", "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", null, "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/Nicht-Opioid-Analgetika#Z99afdd6d3cbead1f5906768c6fecc97e", "/de/wissen/Epileptische_Anf\u00e4lle_und_Epilepsien#Z93dedd171a6efaddb5d27c931860ee21", "/de/wissen/Urtikaria#Ze61f2088492f0f613c664c8409095649", null, "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", null, "/de/wissen/Hormonelle_Kontrazeption#Zc3fe73a267b5941350cfd7fee8e1f20a", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", null, null, null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, null, null, null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, "/de/wissen/Schwindel#Ze8b4c0f0c55909252ceee5f1b6b3fbc5", "/de/wissen/Analgosedierung#Z5c1013b0f02ccf1b6601a686f30f20a7", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Wochenbett#Z8860d9e8ee48d98710828dcee3035d78", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Aszites#Ze557a1ef02d81a491edd9a4ac6aa0c58", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Arterielle_Hypertonie#Z3d73ccc1b405184a8d3087bd8b727eb4", "/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9", "/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874", "/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9", "/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874", "/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9", "/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874", "/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9", null, "/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874", "/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874", "/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9", "/de/wissen/Nuklearmedizin_und_Strahlenschutz#Z1629e94315efb089ad493dbb7ff5a6f1", null, null, "/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874", "/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/Systemische_Amyloidose#Zc1b4ee17fbab831be75bbe7678a1d2e9", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81", "/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874", "/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", null, "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/HIV-Infektion#Z8085d2401472cb7e809cfc2fe50faf6c", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Z8085d2401472cb7e809cfc2fe50faf6c", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, null, "/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261", null, "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Z54541a53e014f60bb262be162cea06e7", "/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02", "/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02", null, "/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02", "/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02", "/de/wissen/Epileptische_Anf\u00e4lle_und_Epilepsien#Z93dedd171a6efaddb5d27c931860ee21", "/de/wissen/Antibiotika_-_\u00dcbersicht#Za6dad35eb36b5da0940872cd1193a503", null, "/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02", null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, null, "/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02", "/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02", "/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02", "/de/wissen/Sinusitis#Ze44c42a5001c509b427969ee14b11f02", null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", null, null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", null, null, null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", null, "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", "/de/wissen/Allergische_Erkrankungen#Z0075153d2fce0d752858b0566e951c5a", "/de/wissen/Antibiotika_-_\u00dcbersicht#Zd988202b12b7ea3fb375dc197d184ccc", "/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3", "/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3", null, null, "/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4", "/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3", "/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3", null, "/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3", null, "/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3", "/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3", null, null, null, null, "/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4", "/de/wissen/Sexualhormone#Zd8af7bfc02d73117787cbdd093cd18b3", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Hypophysenvorderlappeninsuffizienz#Ze6a5e3f834a264b2ebf8c8fdfe50fa37", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", null, "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", null, "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", null, null, "/de/wissen/Vitamine#Z3cebeed83653053fef153c67a295db41", null, null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", null, null, "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", null, null, "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Vitamine#Zb9215d84319323ec614350131f9e006b", null, null, null, null, null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Rauchen_und_Tabakkonsum#Z59e06ec3054a6b1fa6afa36f59825443", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Terminologie#Zbdfd278a2badf97a52d598dc2cd2c497", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/S\u00e4ure-Basen-Haushalt#Za80458cfefac4891bb0c8bbff3987b11", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", null, "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Aminos\u00e4uren_und_Proteine#Z6760651e0606c30942f14701885fce12", null, null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, null, "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", null, "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602", "/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602", "/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151", "/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602", "/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Delir#Zcc15b4e469e0fd3a6d1aac118f7b59b5", "/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Subdurales_H\u00e4matom#Z162bbfd93960992367507851e2ec5602", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", null, "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Allgemeine_Onkologie#Z96dbcb525ee590dbfa7e193aeb93cb24", null, "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z22bbeb78e62fcd17cbdcc573e8ff87cd", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zf1157dfb62b05f3e741ccd036588d15f", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z5c892255c4fb7d1881dd4e503d8aad18", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Nicht-orale_Antikoagulation#Zec68de4bb7f82a9ac0b38e5ae9bf260f", "/de/wissen/Nicht-orale_Antikoagulation#Ze7e718cee0977fa4f04b6436e836e8e8", "/de/wissen/Nicht-orale_Antikoagulation#Z64059939414d9e0325d9fd1e8fcd40ec", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", null, "/de/wissen/Nicht-orale_Antikoagulation#Zad69ea8aed3a6bbd4fda7fc9c0572707", "/de/wissen/Phlebothrombose#Z28ca7507422e8791c7b034c316a126e1", "/de/wissen/Nitrate_und_Molsidomin#Z297e68c91e1cac660e7d5df4acb11c80", "/de/wissen/Allgemeine_Endokrinologie#Z5f7d7972b934850e5dc5e2efdb60e476", "/de/wissen/Nitrate_und_Molsidomin#Z297e68c91e1cac660e7d5df4acb11c80", null, "/de/wissen/Klimakterium#Zac4b020fde98661beb72a24ef0b8c067", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", null, "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", null, "/de/wissen/Klimakterium#Z3338447bd98233f0307b8f0cd29395a1", null, "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Nitrate_und_Molsidomin#Z297e68c91e1cac660e7d5df4acb11c80", "/de/wissen/Nitrate_und_Molsidomin#Zc7d2c406d565ba6a80254c5045509ae7", "/de/wissen/Klimakterium#Zac4b020fde98661beb72a24ef0b8c067", "/de/wissen/Klimakterium#Z6968f8f221cf989eebc438d5fde47c8e", "/de/wissen/One-Minute_Telegram_Archiv#Zddb9aef2b3a93bc9df1e95b94b1f96c5", "/de/wissen/One-Minute_Telegram_Archiv#Z6fff29d49dee9a62e43a4cb98d13bf30", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94", "/de/wissen/One-Minute_Telegram_Archiv#Z440d447048754ea13f8bedfdec8fa4c1", "/de/wissen/One-Minute_Telegram_Archiv#Z107c60c7a1629f12f4f41ada741592fa", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/One-Minute_Telegram_Archiv#Z97a0ccbec6c29b6691a28d0fc581bfc4", "/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Rehabilitation#Z14f5cd16659409413ce2eea2b5ab7e2e", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z9f4a33561601fe529f3c7dfbe30ba130", "/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z76aa6b4f42cf89c1f5aca166ccf1f874", "/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Zaf6487b8c4af3cde01aecd4c7a7d2e26", "/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46", null, "/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46", null, "/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46", null, "/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46", "/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46", "/de/wissen/Perioperatives_Management#Z1e5a3bcca493b7817cfc996c03491dff", "/de/wissen/Perioperatives_Management#Z1e5a3bcca493b7817cfc996c03491dff", "/de/wissen/Perioperatives_Management#Z1e5a3bcca493b7817cfc996c03491dff", "/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46", "/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46", "/de/wissen/Hypertrophe_Kardiomyopathie#Z07f82dfce7a6103e5d9a9205ff70aa46", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, null, null, null, "/de/wissen/Bias,_Stereotype_und_Diskriminierung_in_der_Medizin#Ze3e07d0fda6b5929e2c15428d82c79e3", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", null, "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", null, "/de/wissen/Akutes_Abdomen#Z65fa78006dffd500e2e8d5d58969a49e", "/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94", "/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94", "/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94", "/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94", "/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94", "/de/wissen/Gewebshormone#Z3927d9201d2949947fe08525f6ee490e", "/de/wissen/Tuberkulose#Z7a6f014a08471d76c8dd62b7588d70ad", "/de/wissen/Tuberkulose#Z762fe688a2e0cba3eac698a98a581e94", "/de/wissen/Tuberkulose#Z0db057dcc7fab732110ea50e1288c24c", null, "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", null, "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", null, "/de/wissen/Schwangerschaft#Z7f4a9cfdb95d7dc39e711175bded479e", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Zaf6487b8c4af3cde01aecd4c7a7d2e26", null, "/de/wissen/Malignes_Melanom#Z2ffa13415b57f2d7199ba915fda3575a", "/de/wissen/Plattenepithelkarzinom_der_Haut#Zb0726dcdbb4473b05786feb78ac85bd4", "/de/wissen/Basalzellkarzinom#Z1ec5254615034273183546334da2c821", "/de/wissen/Z\u00e4kum_und_Kolon#Zf16ce71b7846680d613611ebb4f1a33d", "/de/wissen/Z\u00e4kum_und_Kolon#Zf16ce71b7846680d613611ebb4f1a33d", "/de/wissen/Z\u00e4kum_und_Kolon#Zf16ce71b7846680d613611ebb4f1a33d", "/de/wissen/\u00dcbersicht_des_Verdauungssystems#Zaa3f0692fb4127b17e934892e975ec10", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z12db0a61af1774ca03f632559492fe19", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z12db0a61af1774ca03f632559492fe19", "/de/wissen/Z\u00e4kum_und_Kolon#Zf16ce71b7846680d613611ebb4f1a33d", "/de/wissen/Divertikulose,_Divertikelkrankheit_und_Divertikulitis#Zef9b81a8be3a2511a46e79e9e075b8c7", "/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0", "/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0", "/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0", "/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0", "/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4", "/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4", "/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0", "/de/wissen/Nierendurchblutung_und_glomerul\u00e4re_Filtration#Ze2ec510bc7d269d804f7dbd8f36661ab", "/de/wissen/RAAS-Inhibitoren#Zd6e8a87204059b03487185fade42af31", "/de/wissen/Nebenniere#Z677ca6e3187a3c17aa608668dbb243eb", "/de/wissen/RAAS-Inhibitoren#Zd6e8a87204059b03487185fade42af31", "/de/wissen/RAAS-Inhibitoren#Zd6e8a87204059b03487185fade42af31", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4", "/de/wissen/Herzinsuffizienz#Zd2c9b2c7d8e1f3e96478a8e02b0cf7d0", "/de/wissen/Herzinsuffizienz#Z6df09d54c6c264a5c6e2889576ba3477", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Pharmakologische_Grundlagen#Z6ae7121c68f777dd7f545ea0bc75299f", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z865d37347a16e85f2cb7f1265b6c766b", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", null, null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Antidepressiva#Z212f29b4df419c67d6a29424f6b9ebe0", "/de/wissen/Antidepressiva#Z212f29b4df419c67d6a29424f6b9ebe0", null, null, "/de/wissen/Lithium#Zc20878d1fde3b53f47307e0a8d3ccbae", null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", null, null, "/de/wissen/Antidepressiva#Z212f29b4df419c67d6a29424f6b9ebe0", "/de/wissen/Antidepressiva#Z212f29b4df419c67d6a29424f6b9ebe0", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z34d41b30a792b17afcdd32b43ce85f19", "/de/wissen/Bias,_Stereotype_und_Diskriminierung_in_der_Medizin#Zefcdff057a499d78914350d631b15287", "/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81", null, null, "/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81", "/de/wissen/Allgemeinan\u00e4sthesie#Zea846d3465d1a392fbf008b5131bf900", null, "/de/wissen/\u00dcbersicht_des_Verdauungssystems#Zaa3f0692fb4127b17e934892e975ec10", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/Allgemeinan\u00e4sthesie#Zea846d3465d1a392fbf008b5131bf900", null, "/de/wissen/\u00dcbersicht_des_Verdauungssystems#Zaa3f0692fb4127b17e934892e975ec10", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", null, null, "/de/wissen/Pneumonie#Z00605b3af0c051b1bf6170708112bd0c", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Arthrose#Z02ddc3c6fe4fae13fc187533ee2e65ba", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, null, null, "/de/wissen/Sexualhormone#Z30990f86bf408f16b9e5b25eaa0a1065", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Sexualhormone#Z30990f86bf408f16b9e5b25eaa0a1065", "/de/wissen/Prostatakarzinom#Z8177a7d89a41809da02205b21a7b3283", "/de/wissen/One-Minute_Telegram_Archiv#Zd4f88ef0ae8120cfba5d26c551223bb4", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/One-Minute_Telegram_Archiv#Z3bc56eab38bd731fd8976865e9039c20", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/One-Minute_Telegram_Archiv#Z2cc6695f2c802cebbaa177964b1c9a4e", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/One-Minute_Telegram_Archiv#Z3bcdbf81f579eff597aff89f336e7dd5", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/One-Minute_Telegram_Archiv#Zf30f386211b8b086a1e9fc2354cb1eb4", "/de/wissen/Neurologische_Untersuchung#Z287079ef7739f4e5dc8bbdef88adaea4", null, "/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/One-Minute_Telegram_Archiv#Z0e7fa357b14a93221ec72113b8aee537", "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", "/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8", "/de/wissen/Lungenfunktionsuntersuchung#Z80d949a4d2a4efc1d0698d7d68ac9d2b", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Antibiotika_-_\u00dcbersicht#Zc2b39f2fb480726a0e60f8f676834a72", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", "/de/wissen/Lungenfunktionsuntersuchung#Z80d949a4d2a4efc1d0698d7d68ac9d2b", "/de/wissen/Tuberkulose#Z0a185ef468711f3a4465556d1e8632ec", "/de/wissen/Tuberkulose#Z8800fb076b10b48b18eb61516d6cddd7", "/de/wissen/Pneumonie#Zebe53f3ed128a0207d97b438c04b867b", "/de/wissen/Antibiotika_-_\u00dcbersicht#Zc2b39f2fb480726a0e60f8f676834a72", "/de/wissen/Antibiotika_-_\u00dcbersicht#Zc2b39f2fb480726a0e60f8f676834a72", "/de/wissen/Audiometrische_Verfahren_in_der_HNO#Z7557366df45a5d8254c0fba4a82c9b27", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Lungenfunktionsuntersuchung#Z80d949a4d2a4efc1d0698d7d68ac9d2b", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Tuberkulose#Z0db057dcc7fab732110ea50e1288c24c", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/S\u00e4ure-Basen-Haushalt#Za80458cfefac4891bb0c8bbff3987b11", "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/S\u00e4ure-Basen-Haushalt#Za80458cfefac4891bb0c8bbff3987b11", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipidsenker#Z1e78ee2e8336d5ff15ddeae7ef13d569", "/de/wissen/Lipidsenker#Zc0c8744cee387048609bafe6c953e2dd", "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/Lipidsenker#Z1e78ee2e8336d5ff15ddeae7ef13d569", "/de/wissen/Lipidsenker#Zc0c8744cee387048609bafe6c953e2dd", "/de/wissen/S\u00e4ure-Basen-Haushalt#Za80458cfefac4891bb0c8bbff3987b11", "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z139361cb7eef098487c30705ba4a7975", "/de/wissen/Koronare_Herzkrankheit#Zfbf6e89e4c99b090c46d60c93fdd8ff1", "/de/wissen/Dyslipid\u00e4mien#Z6f17254a240deb056c9f82d3fa69fac5", "/de/wissen/Thiaziddiuretika#Z326ee0b85f1a9567b91f36bfd180cda2", "/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c", "/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c", "/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8", "/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c", null, null, "/de/wissen/Thiaziddiuretika#Z326ee0b85f1a9567b91f36bfd180cda2", "/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c", "/de/wissen/Wasser-_und_Elektrolythaushalt#Zca6be39e404895ed291688b168784eca", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, null, "/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261", null, "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", null, "/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8", "/de/wissen/Urolithiasis#Z85d5b5ec71af050aa1f8cd0d7c05d15c", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", null, "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", null, "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", null, null, "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Allgemeine_Virologie#Z11a82adcd836a563c7df38236c862d06", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Immunsuppressiva#Zc4f8bb61c1be8bf782272d0e9b088995", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/Aminos\u00e4uren_und_Proteine#Z6760651e0606c30942f14701885fce12", "/de/wissen/\u00dcbersicht_Geriatrie#Zd974d45f1bd7586d4a4b49bc962e9adc", "/de/wissen/Akute_Bronchitis#Zeee17e2aa0c0e653e43bea1bf81c386b", "/de/wissen/Herpesvirus-Infektionen#Z919b941a8193eedb0ce87b453ae9885e", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Herpesvirus-Infektionen#Z919b941a8193eedb0ce87b453ae9885e", "/de/wissen/Sexuell_\u00fcbertragbare_Infektionen#Zf2a474fc86c5ef68694e80ca13cd405b", "/de/wissen/Wasser-_und_Elektrolythaushalt#Zca6be39e404895ed291688b168784eca", null, "/de/wissen/Periphere_arterielle_Verschlusskrankheit#Z1e2af43306a42a2270c69be33f51a20b", "/de/wissen/Periphere_arterielle_Verschlusskrankheit#Z1e2af43306a42a2270c69be33f51a20b", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Insomnien#Z5e4895500dbde306d029b711e2ea238b", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", null, null, null, "/de/wissen/Atemwege_und_Lunge#Zbffa82a865686699ed8a6fc3276b5293", "/de/wissen/Acute_Respiratory_Distress_Syndrome#Z154aa7c6d0bde152f7ea366b2d6834d0", "/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z87e9a247724c9b2410076167606f4c20", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Psychotherapeutische_Verfahren_(Klinik)#Z287bafc91b62572585c8c77c0a431a84", null, "/de/wissen/\u00dcbersicht_Geriatrie#Zd974d45f1bd7586d4a4b49bc962e9adc", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", null, "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", null, null, "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", null, "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z3cebeed83653053fef153c67a295db41", "/de/wissen/Vitamine#Z3cebeed83653053fef153c67a295db41", null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Becken_und_H\u00fcfte#Z0258fe63773be508fb74c6409eb1e1f9", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Nicht-orale_Antikoagulation#Z192af13319e60e9a995bf18736ec3b1a", "/de/wissen/Phlebothrombose#Z28ca7507422e8791c7b034c316a126e1", "/de/wissen/Lungenembolie#Z109ebdc29405d0f0b7670dc604254fcd", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Nicht-orale_Antikoagulation#Zad69ea8aed3a6bbd4fda7fc9c0572707", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/Audiometrische_Verfahren_in_der_HNO#Z7557366df45a5d8254c0fba4a82c9b27", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/Herzinsuffizienz#Z159958c8b33e83f2f05f57847f5139ff", "/de/wissen/Schleifendiuretika#Za83341d27dcd429ba35ac446fd574de8", "/de/wissen/Herzmechanik#Zddad2b2b7b5aed13343302b8c1df42e4", null, "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Aufbau_von_DNA_und_RNA#Zc937104d20e3073b9c1a31fba7065b8d", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolonpolypen#Z7d836a80066e57b74c74add53eea2731", "/de/wissen/Neurologische_Untersuchung#Z287079ef7739f4e5dc8bbdef88adaea4", null, null, null, null, "/de/wissen/Studientypen_der_medizinischen_Forschung#Z12db0a61af1774ca03f632559492fe19", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266", null, "/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Tubul\u00e4re_Transportprozesse#Z147bc6f1ad1901fc8ed06311e1ce0e9f", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", null, null, "/de/wissen/Laboratoriumsmedizin#Z17520cb42bfb4e42a2e7ab25d2d0dd78", "/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398", null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398", null, null, "/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", null, null, "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Antidiabetika#Z8cb9f0d09ce5db412af4be69feb68a26", "/de/wissen/Antidiabetika#Z414a9aa4b418f60def3522ed0dc60398", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Nervengewebe,_Synapsen_und_Transmitter#Zabfae2472ee779feb0ae2fba3c36e946", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", null, null, null, null, "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", null, null, null, "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", null, "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", null, null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", null, null, "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", null, null, "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", null, "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de", "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", null, null, "/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b", "/de/wissen/Koronare_Herzkrankheit#Zfbf6e89e4c99b090c46d60c93fdd8ff1", "/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8", "/de/wissen/Thiaziddiuretika#Z326ee0b85f1a9567b91f36bfd180cda2", "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", "/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", "/de/wissen/Arterielle_Hypertonie#Z3d73ccc1b405184a8d3087bd8b727eb4", "/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b", "/de/wissen/Koronare_Herzkrankheit#Zfbf6e89e4c99b090c46d60c93fdd8ff1", "/de/wissen/Thiaziddiuretika#Zd424685f847ef6326e4d11e8a5bf38f8", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", null, "https://dx.doi.org/10.1001/jama.2023.5747", "https://read.qxmd.com/doi/10.1001/jama.2023.5747", "https://dx.doi.org/10.1056/nejmoa2204462", "https://read.qxmd.com/doi/10.1056/nejmoa2204462", "https://dx.doi.org/10.1001/jamahealthforum.2023.0136", "https://read.qxmd.com/doi/10.1001/jamahealthforum.2023.0136", "https://dx.doi.org/10.1001/jama.2023.14461", "https://read.qxmd.com/doi/10.1001/jama.2023.14461", "https://dx.doi.org/10.1001/jamanetworkopen.2023.27647", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2023.27647", "https://dx.doi.org/10.1016/s0140-6736(23)01240-0", "https://read.qxmd.com/doi/10.1016/s0140-6736(23)01240-0", "https://dx.doi.org/10.1056/nejmoa2215025", "https://read.qxmd.com/doi/10.1056/nejmoa2215025", "https://dx.doi.org/10.1136/bmj-2023-075230", "https://read.qxmd.com/doi/10.1136/bmj-2023-075230", "https://dx.doi.org/10.1001/jama.2023.10042", "https://read.qxmd.com/doi/10.1001/jama.2023.10042", "https://dx.doi.org/10.1001/jama.2023.4342", "https://read.qxmd.com/doi/10.1001/jama.2023.4342", "https://dx.doi.org/10.1001/jamasurg.2023.0466", "https://read.qxmd.com/doi/10.1001/jamasurg.2023.0466", "https://dx.doi.org/10.1016/j.jacadv.2023.100289", "https://read.qxmd.com/doi/10.1016/j.jacadv.2023.100289", "https://dx.doi.org/10.1093/eurheartj/ehz425", "https://read.qxmd.com/doi/10.1093/eurheartj/ehz425", "https://dx.doi.org/10.1016/j.jacc.2020.09.585", "https://read.qxmd.com/doi/10.1016/j.jacc.2020.09.585", "https://dx.doi.org/10.1016/j.jacc.2021.07.053", "https://read.qxmd.com/doi/10.1016/j.jacc.2021.07.053", "https://dx.doi.org/10.1161/jaha.122.027260", "https://read.qxmd.com/doi/10.1161/jaha.122.027260", "https://dx.doi.org/10.1161/hyp.0000000000000066", "https://read.qxmd.com/doi/10.1161/hyp.0000000000000066", "https://dx.doi.org/10.1001/jamainternmed.2019.7454", "https://read.qxmd.com/doi/10.1001/jamainternmed.2019.7454", "https://dx.doi.org/10.1056/nejmoa2212270", "https://read.qxmd.com/doi/10.1056/nejmoa2212270", "https://dx.doi.org/10.1161/circulationaha.122.061288", "https://read.qxmd.com/doi/10.1161/circulationaha.122.061288", "https://dx.doi.org/10.1056/nejmoa2212663", "https://read.qxmd.com/doi/10.1056/nejmoa2212663", "https://dx.doi.org/10.1001/jamainternmed.2022.6545", "https://read.qxmd.com/doi/10.1001/jamainternmed.2022.6545", "https://dx.doi.org/10.7326/m22-3018", "https://read.qxmd.com/doi/10.7326/m22-3018", "https://dx.doi.org/10.1056/nejmoa2304146", "https://read.qxmd.com/doi/10.1056/nejmoa2304146", "https://dx.doi.org/10.1001/jama.2023.10854", "https://read.qxmd.com/doi/10.1001/jama.2023.10854", "https://dx.doi.org/10.1001/jamainternmed.2023.2986", "https://read.qxmd.com/doi/10.1001/jamainternmed.2023.2986", "https://dx.doi.org/10.1056/nejmoa2307227", "https://read.qxmd.com/doi/10.1056/nejmoa2307227", "https://dx.doi.org/10.1001/jamacardio.2023.3364", "https://read.qxmd.com/doi/10.1001/jamacardio.2023.3364", "https://dx.doi.org/10.1056/nejmoa2304855", "https://read.qxmd.com/doi/10.1056/nejmoa2304855", "https://dx.doi.org/10.1001/jamasurg.2023.1112", "https://read.qxmd.com/doi/10.1001/jamasurg.2023.1112", "https://dx.doi.org/10.1001/jama.2023.4899", "https://read.qxmd.com/doi/10.1001/jama.2023.4899", "https://dx.doi.org/10.1056/nejmoa2214470", "https://read.qxmd.com/doi/10.1056/nejmoa2214470", "https://dx.doi.org/10.1136/bmj-2022-074450", "https://read.qxmd.com/doi/10.1136/bmj-2022-074450", "https://dx.doi.org/10.1001/jama.2023.14590", "https://read.qxmd.com/doi/10.1001/jama.2023.14590", "https://dx.doi.org/10.1056/nejmoa2300468", "https://read.qxmd.com/doi/10.1056/nejmoa2300468", "https://dx.doi.org/10.1056/nejmoa2209604", "https://read.qxmd.com/doi/10.1056/nejmoa2209604", "https://dx.doi.org/10.1001/jama.2023.0057", "https://read.qxmd.com/doi/10.1001/jama.2023.0057", "https://dx.doi.org/10.1161/jaha.122.027361", "https://read.qxmd.com/doi/10.1161/jaha.122.027361", "https://dx.doi.org/10.1056/nejmoa2216767", "https://read.qxmd.com/doi/10.1056/nejmoa2216767", "https://dx.doi.org/10.1001/jama.2023.7843", "https://read.qxmd.com/doi/10.1001/jama.2023.7843", "https://dx.doi.org/10.1001/jamainternmed.2023.1977", "https://read.qxmd.com/doi/10.1001/jamainternmed.2023.1977", "https://dx.doi.org/10.1056/nejmoa2212537", "https://read.qxmd.com/doi/10.1056/nejmoa2212537", "https://dx.doi.org/10.1001/jama.2023.2487", "https://read.qxmd.com/doi/10.1001/jama.2023.2487", "https://dx.doi.org/10.1056/nejmoa2209275", "https://read.qxmd.com/doi/10.1056/nejmoa2209275", "https://dx.doi.org/10.1056/nejmoa2205973", "https://read.qxmd.com/doi/10.1056/nejmoa2205973", "https://dx.doi.org/10.1001/jama.2022.23924", "https://read.qxmd.com/doi/10.1001/jama.2022.23924", "https://dx.doi.org/10.1001/jamanetworkopen.2022.51384", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2022.51384", "https://dx.doi.org/10.1016/j.hrthm.2017.01.038", "https://read.qxmd.com/doi/10.1016/j.hrthm.2017.01.038", "https://dx.doi.org/10.1056/nejmoa2029980", "https://read.qxmd.com/doi/10.1056/nejmoa2029980", "https://dx.doi.org/10.1056/nejmoa2212540", "https://read.qxmd.com/doi/10.1056/nejmoa2212540", "https://dx.doi.org/10.1056/nejmoa2024816", "https://read.qxmd.com/doi/10.1056/nejmoa2024816", "https://dx.doi.org/10.1056/nejmoa1811744", "https://read.qxmd.com/doi/10.1056/nejmoa1811744", "https://dx.doi.org/10.1056/nejmoa2204233", "https://read.qxmd.com/doi/10.1056/nejmoa2204233", "https://dx.doi.org/10.1001/jamanetworkopen.2022.6269", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2022.6269", "https://dx.doi.org/10.1126/scitranslmed.aau5266", "https://read.qxmd.com/doi/10.1126/scitranslmed.aau5266", "https://dx.doi.org/10.1016/j.jclinepi.2020.04.025", "https://read.qxmd.com/doi/10.1016/j.jclinepi.2020.04.025", "https://dx.doi.org/10.1001/jama.2022.24100", "https://read.qxmd.com/doi/10.1001/jama.2022.24100", "https://dx.doi.org/10.1176/appi.ajp.20220785", "https://read.qxmd.com/doi/10.1176/appi.ajp.20220785", "https://dx.doi.org/10.1001/jamainternmed.2023.3264", "https://read.qxmd.com/doi/10.1001/jamainternmed.2023.3264", "https://dx.doi.org/10.1001/jama.2023.13239", "https://read.qxmd.com/doi/10.1001/jama.2023.13239", "https://dx.doi.org/10.1001/jama.2023.16991", "https://read.qxmd.com/doi/10.1001/jama.2023.16991", "https://dx.doi.org/10.1001/jamanetworkopen.2023.34540", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2023.34540", "https://dx.doi.org/10.1056/nejmoa2306963", "https://read.qxmd.com/doi/10.1056/nejmoa2306963", "https://dx.doi.org/10.1056/nejmoa2215145", "https://read.qxmd.com/doi/10.1056/nejmoa2215145", "https://dx.doi.org/10.1001/jamanetworkopen.2023.3646", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2023.3646", "https://dx.doi.org/10.1056/nejmoa2214122", "https://read.qxmd.com/doi/10.1056/nejmoa2214122", "https://dx.doi.org/10.1056/nejmsa2212412", "https://read.qxmd.com/doi/10.1056/nejmsa2212412", "https://dx.doi.org/10.1001/jamacardio.2023.1042", "https://read.qxmd.com/doi/10.1001/jamacardio.2023.1042", "https://dx.doi.org/10.1001/jama.2023.7022", "https://read.qxmd.com/doi/10.1001/jama.2023.7022", "https://dx.doi.org/10.1001/jama.2023.9301", "https://read.qxmd.com/doi/10.1001/jama.2023.9301", "https://dx.doi.org/10.1001/jama.2023.9297", "https://read.qxmd.com/doi/10.1001/jama.2023.9297", "https://dx.doi.org/10.1056/nejmoa2303208", "https://read.qxmd.com/doi/10.1056/nejmoa2303208", "https://dx.doi.org/10.1001/jama.2023.9696", "https://read.qxmd.com/doi/10.1001/jama.2023.9696", "https://www.amboss.com", "/de/wissen", "https://www.amboss.com/de/other/agb", "https://www.amboss.com/de/other/disclaimer", "https://www.amboss.com/de/other/datenschutz", "#", "https://www.amboss.com/de/impressum", "https://support.amboss.com/hc/de", "https://www.amboss.com/de/account/login?nextLink=%2Farticle%2FJF0sQ3", "https://www.amboss.com/de/account/register?nextLink=%2Farticle%2FJF0sQ3", "https://www.amboss.com/de/disclaimer"]}